<!DOCTYPE html>
<!--[if IE 7]>                  <html class="ie7 no-js" lang="en" dir="ltr"
  xmlns:og="http://ogp.me/ns#"
  xmlns:article="http://ogp.me/ns/article#"
  xmlns:book="http://ogp.me/ns/book#"
  xmlns:profile="http://ogp.me/ns/profile#"
  xmlns:video="http://ogp.me/ns/video#"
  xmlns:product="http://ogp.me/ns/product#">     <![endif]-->
<!--[if lte IE 8]>              <html class="ie8 no-js" lang="en" dir="ltr"
  xmlns:og="http://ogp.me/ns#"
  xmlns:article="http://ogp.me/ns/article#"
  xmlns:book="http://ogp.me/ns/book#"
  xmlns:profile="http://ogp.me/ns/profile#"
  xmlns:video="http://ogp.me/ns/video#"
  xmlns:product="http://ogp.me/ns/product#">     <![endif]-->
<!--[if (gte IE 9)|!(IE)]><!--> <html class="not-ie no-js" lang="en" dir="ltr"
  xmlns:og="http://ogp.me/ns#"
  xmlns:article="http://ogp.me/ns/article#"
  xmlns:book="http://ogp.me/ns/book#"
  xmlns:profile="http://ogp.me/ns/profile#"
  xmlns:video="http://ogp.me/ns/video#"
  xmlns:product="http://ogp.me/ns/product#">  <!--<![endif]-->
<head>
  <!--[if IE]><![endif]-->
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<link rel="shortcut icon" href="../sites/default/files/Favicon2.png" type="image/png" />
<meta name="description" content="U.S. Department of Health and Human Services National Estimates of Prescription Drug Utilization and Expenditures in Long-Term Care Facilities Linda Simoni-Wastila, PhD, Thomas Shaffer, MHS and Bruce Stuart, PhD University of Maryland, Baltimore, Peter Lamy Center on Drug Therapy and Aging October 25, 2006 PDF Version (23 PDF pages)" />
<meta name="generator" content="Drupal 7 (http://drupal.org)" />
<link rel="canonical" href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html" />
<link rel="shortlink" href="https://aspe.hhs.gov/node/68951" />
<meta property="og:site_name" content="ASPE" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://aspe.hhs.gov/basic-report/national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities" />
<meta property="og:title" content="National Estimates of Prescription Drug Utilization and Expenditures in Long-Term Care Facilities" />
<meta property="og:description" content="U.S. Department of Health and Human Services National Estimates of Prescription Drug Utilization and Expenditures in Long-Term Care Facilities Linda Simoni-Wastila, PhD, Thomas Shaffer, MHS and Bruce Stuart, PhD University of Maryland, Baltimore, Peter Lamy Center on Drug Therapy and Aging October 25, 2006 PDF Version (23 PDF pages)" />
<meta property="og:updated_time" content="2017-02-21T11:34:26-05:00" />
<meta property="article:published_time" content="2015-06-13T04:08:31-04:00" />
<meta property="article:modified_time" content="2017-02-21T11:34:26-05:00" />

  <title>National Estimates of Prescription Drug Utilization and Expenditures in Long-Term Care Facilities | ASPE</title>
	<meta http-equiv="X-UA-Compatible" content="IE=edge"><script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function(e,n,t){function r(t){if(!n[t]){var o=n[t]={exports:{}};e[t][0].call(o.exports,function(n){var o=e[t][1][n];return r(o||n)},o,o.exports)}return n[t].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<t.length;o++)r(t[o]);return r}({1:[function(e,n,t){function r(){}function o(e,n,t){return function(){return i(e,[c.now()].concat(u(arguments)),n?null:this,t),n?void 0:this}}var i=e("handle"),a=e(2),u=e(3),f=e("ee").get("tracer"),c=e("loader"),s=NREUM;"undefined"==typeof window.newrelic&&(newrelic=s);var p=["setPageViewName","setCustomAttribute","setErrorHandler","finished","addToTrace","inlineHit","addRelease"],d="api-",l=d+"ixn-";a(p,function(e,n){s[n]=o(d+n,!0,"api")}),s.addPageAction=o(d+"addPageAction",!0),s.setCurrentRouteName=o(d+"routeName",!0),n.exports=newrelic,s.interaction=function(){return(new r).get()};var m=r.prototype={createTracer:function(e,n){var t={},r=this,o="function"==typeof n;return i(l+"tracer",[c.now(),e,t],r),function(){if(f.emit((o?"":"no-")+"fn-start",[c.now(),r,o],t),o)try{return n.apply(this,arguments)}finally{f.emit("fn-end",[c.now()],t)}}}};a("setName,setAttribute,save,ignore,onEnd,getContext,end,get".split(","),function(e,n){m[n]=o(l+n)}),newrelic.noticeError=function(e){"string"==typeof e&&(e=new Error(e)),i("err",[e,c.now()])}},{}],2:[function(e,n,t){function r(e,n){var t=[],r="",i=0;for(r in e)o.call(e,r)&&(t[i]=n(r,e[r]),i+=1);return t}var o=Object.prototype.hasOwnProperty;n.exports=r},{}],3:[function(e,n,t){function r(e,n,t){n||(n=0),"undefined"==typeof t&&(t=e?e.length:0);for(var r=-1,o=t-n||0,i=Array(o<0?0:o);++r<o;)i[r]=e[n+r];return i}n.exports=r},{}],4:[function(e,n,t){n.exports={exists:"undefined"!=typeof window.performance&&window.performance.timing&&"undefined"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(e,n,t){function r(){}function o(e){function n(e){return e&&e instanceof r?e:e?f(e,u,i):i()}function t(t,r,o,i){if(!d.aborted||i){e&&e(t,r,o);for(var a=n(o),u=m(t),f=u.length,c=0;c<f;c++)u[c].apply(a,r);var p=s[y[t]];return p&&p.push([b,t,r,a]),a}}function l(e,n){v[e]=m(e).concat(n)}function m(e){return v[e]||[]}function w(e){return p[e]=p[e]||o(t)}function g(e,n){c(e,function(e,t){n=n||"feature",y[t]=n,n in s||(s[n]=[])})}var v={},y={},b={on:l,emit:t,get:w,listeners:m,context:n,buffer:g,abort:a,aborted:!1};return b}function i(){return new r}function a(){(s.api||s.feature)&&(d.aborted=!0,s=d.backlog={})}var u="nr@context",f=e("gos"),c=e(2),s={},p={},d=n.exports=o();d.backlog=s},{}],gos:[function(e,n,t){function r(e,n,t){if(o.call(e,n))return e[n];var r=t();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,n,{value:r,writable:!0,enumerable:!1}),r}catch(i){}return e[n]=r,r}var o=Object.prototype.hasOwnProperty;n.exports=r},{}],handle:[function(e,n,t){function r(e,n,t,r){o.buffer([e],r),o.emit(e,n,t)}var o=e("ee").get("handle");n.exports=r,r.ee=o},{}],id:[function(e,n,t){function r(e){var n=typeof e;return!e||"object"!==n&&"function"!==n?-1:e===window?0:a(e,i,function(){return o++})}var o=1,i="nr@id",a=e("gos");n.exports=r},{}],loader:[function(e,n,t){function r(){if(!x++){var e=h.info=NREUM.info,n=d.getElementsByTagName("script")[0];if(setTimeout(s.abort,3e4),!(e&&e.licenseKey&&e.applicationID&&n))return s.abort();c(y,function(n,t){e[n]||(e[n]=t)}),f("mark",["onload",a()+h.offset],null,"api");var t=d.createElement("script");t.src="https://"+e.agent,n.parentNode.insertBefore(t,n)}}function o(){"complete"===d.readyState&&i()}function i(){f("mark",["domContent",a()+h.offset],null,"api")}function a(){return E.exists&&performance.now?Math.round(performance.now()):(u=Math.max((new Date).getTime(),u))-h.offset}var u=(new Date).getTime(),f=e("handle"),c=e(2),s=e("ee"),p=window,d=p.document,l="addEventListener",m="attachEvent",w=p.XMLHttpRequest,g=w&&w.prototype;NREUM.o={ST:setTimeout,CT:clearTimeout,XHR:w,REQ:p.Request,EV:p.Event,PR:p.Promise,MO:p.MutationObserver};var v=""+location,y={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-1026.min.js"},b=w&&g&&g[l]&&!/CriOS/.test(navigator.userAgent),h=n.exports={offset:u,now:a,origin:v,features:{},xhrWrappable:b};e(1),d[l]?(d[l]("DOMContentLoaded",i,!1),p[l]("load",r,!1)):(d[m]("onreadystatechange",o),p[m]("onload",r)),f("mark",["firstbyte",u],null,"api");var x=0,E=e(4)},{}]},{},["loader"]);</script>

	<!-- Mobile Specific Metas
	================================================== -->
	<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=1.0,user-scalable=0">

  <link type="text/css" rel="stylesheet" href="../sites/default/files/advagg_css/css__5ln8neBOcJfyUveiD4y9fhI6kHBLOQ_YL0mMC-LS9a0__TPJIZT9UBnf_685NlFTJ5KnZVsjwFk6ACQ-nwwygmwU__YASpjlMF4TMWgxnen_4K9EYMAww1U3QElt83Z7yKaXw.css" media="all" />
<link type="text/css" rel="stylesheet" href="../sites/default/files/advagg_css/css__ng49uRH5y4Hl9VF9hHW_vXOj-mcOc2u2ShJqJ1YKIGU__FoMCD14GBvZaRiqSQ_JpP1w3rDB21n7H2Ar4pRZaIh8__YASpjlMF4TMWgxnen_4K9EYMAww1U3QElt83Z7yKaXw.css" media="all" />
<link type="text/css" rel="stylesheet" href="../sites/default/files/advagg_css/css__Hskudx14OJ5Hz8vqU7CUgN6SDV5rINZuEq9VuGsSeyc__EwNIl3xeFrniW2TmonovTzhSs3X5MdFps210puE7jog__YASpjlMF4TMWgxnen_4K9EYMAww1U3QElt83Z7yKaXw.css" media="all" />
<link type="text/css" rel="stylesheet" href="../sites/default/files/advagg_css/css__9rZoaX9BdzjjNucvYxduxeNAVO2zgW_Rvjhb5rq5whc__lSr_y16grDSgHf4booPChnF7QXz3TQY3hafH49twE0k__YASpjlMF4TMWgxnen_4K9EYMAww1U3QElt83Z7yKaXw.css" media="all" />
<link type="text/css" rel="stylesheet" href="../sites/default/files/advagg_css/css__ZgfI_ZPib5yVY0o5aKo_6TFn946Tuu_nFDa0ySTmkSc__2FTFrNw2eNh0mpHIOA34r6YRwBZMm2PjJ_JubnwLigg__YASpjlMF4TMWgxnen_4K9EYMAww1U3QElt83Z7yKaXw.css" media="all" />
<link type="text/css" rel="stylesheet" href="../sites/default/files/advagg_css/css__dxabpJ5rQgDSixKgLJZjWc1beC6mpROKwVrmWxI5eno__rqhz_hGsE_i59O7-W991o71_Jxw1QOtGMxn4nsOLHY8__YASpjlMF4TMWgxnen_4K9EYMAww1U3QElt83Z7yKaXw.css" media="all" />
<link type="text/css" rel="stylesheet" href="../sites/default/files/advagg_css/css__ZbRCq2NqWgK-HXAQI3So0N1n0nr4HonsJS3eQuuxukw__7Olkk8Locn8Dj0eR0Ww3rbV9lks9sxipcboMXB18RRs__YASpjlMF4TMWgxnen_4K9EYMAww1U3QElt83Z7yKaXw.css" media="all" />

	<!-- Head Libs -->
	<script src="../sites/all/themes/stability/stability_aspe/vendor/modernizr.js"></script>

	<!--[if lt IE 9]>
		<script src="http://html5shim.googlecode.com/svn/trunk/html5.js"></script>
		<script src="/sites/all/themes/stability/vendor/respond.min.js"></script>
	<![endif]-->

	<!-- Favicons
	================================================== -->
	<link rel="apple-touch-icon" href="../sites/all/themes/stability/images/apple-touch-icon.png">
	<link rel="apple-touch-icon" sizes="72x72" href="../sites/all/themes/stability/images/apple-touch-icon-72x72.png">
	<link rel="apple-touch-icon" sizes="114x114" href="../sites/all/themes/stability/images/apple-touch-icon-114x114.png">
	<link rel="apple-touch-icon" sizes="144x144" href="../sites/all/themes/stability/images/apple-touch-icon-144x144.png">

</head>
<body class="html not-front not-logged-in no-sidebars page-node page-node- page-node-68951 node-type-basic-report">
<!-- Google Tag Manager -->
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-JLFR"
                  height="0" width="0" style="display:none;visibility:hidden" title="googletagmanager"></iframe></noscript>
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
    new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
    j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
    '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
  })(window,document,'script','dataLayer','GTM-JLFR');</script>
<!-- End Google Tag Manager -->
  <div id="skip-nav" class="accessibility_menu">
    <strong>Shortcut Navigation:</strong>
    <ul>
      <li><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#content" accesskey="c" title="Skip to page content (ctrl/alt + c)">Page Content</a></li>
      <li><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#nav" accesskey="m" title="Skip to main navigation menu (ctrl/alt + m)">Site Navigation</a></li>

      <li><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#Footer" accesskey="f" title="Skip to footer (ctrl/alt + f)">Footer</a></li>
    </ul>
  </div>


<div class="site-wrapper">

  <header class="header header-menu-fullw header-top-clean">
    <div id="brand-bar">
        <div class="container">
                    <img alt='bird' src="../sites/all/themes/stability/stability_aspe/images/bird.png"> <a target="blank" tabindex="4" href="http://www.hhs.gov/">U.S. Department of Health & Human Services</a>
        </div>

    </div>
    <div class="header-main">
        <div class="container clearfix">
            <div class="social-links-wrapper">
                <ul class="social-links social-links__light">
                                                          <li><a href="http://twitter.com/hhs_aspe"><img alt="twitter" src="../sites/all/themes/stability/stability_aspe/images/tw.png"/></a></li>
                                    <!--                  --><!--                    <li><a href="http://--><!--"><img alt="linkedin" src="--><!--/images/linkedin.png"/></a></li>-->
<!--                  -->
                                                                      </ul>
            </div>
            <!-- Logo -->
            <div class="logo">
                                <div class="site_name_wrapper">
                                     <span class="h1">
                                      <a href="../images/exit_disclaimer.jpg.html">ASPE</a>
                                       </span>
                                  <p class="tagline"><p>Office of The Assistant Secretary</p><p> for Planning and Evaluation</p></p>
                    </div>
            </div>
            <!-- Logo / End -->
            <div class="header_right_wrapper">
                <div class="search-form">
                    <form action="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html" method="post" id="search-block-form" accept-charset="UTF-8"><div><div class="container-inline">
  <div class = "input-group"><div class="form-type-textfield form-item-search-block-form form-item form-group">
  <label class="element-invisible" for="edit-search-block-form--2">Search </label>
 <input title="Enter the terms you wish to search for." placeholder="Search Site..." class="form-control form-control form-text" type="text" id="edit-search-block-form--2" name="search_block_form" value="" size="15" maxlength="128" />
</div>
<div class="form-actions form-wrapper" id="edit-actions--2"><input class="btn btn-primary btn-icon form-submit" type="image" id="edit-submit" name="submit" value="Search" src="../sites/all/themes/stability/stability_aspe/images/search-white2.png" alt="Search" title="Search" /></div></div><input type="hidden" name="form_build_id" value="form-9XKQ1w0OKclWef14kVU_J4UHpUS2ibJNV5ahOAnPxaE" />
<input type="hidden" name="form_id" value="search_block_form" />
</div>
</div></form>                </div>
                <button type="button" class="navbar-toggle" value="Menu">
                    <i class="fa fa-bars"></i>Menu
                </button>
            </div>

        </div>
    </div>

    <!-- Navigation -->
    <nav id="nav" class="nav-main">
        <div class="container">
          <ul data-breakpoint="767" class="flexnav">
                <li class="first expanded"><a href="../basic-search/about.html" title="">About</a><ul><li class="first leaf"><a href="../node/41366.html" title="">Mission</a></li>
<li class="leaf"><a href="../key-staff.html" title="">Leadership</a></li>
<li class="leaf"><a href="https://www.usajobs.gov/" title="">Careers</a></li>
<li class="expanded"><a href="../node/83081.html" title="linkTo">Coordination</a><ul><li class="first leaf"><a href="../node/94561.html" title="">Evaluation &amp; Evidence</a></li>
<li class="leaf"><a href="../node/83126.html">National Alzheimer&#039;s Project Act</a></li>
<li class="leaf"><a href="../hhs-data-council.html">HHS Data Council</a></li>
<li class="last leaf"><a href="../node/83076.html" title="National Council on Vital and Health Statistics">National Council on Vital and Health Statistics</a></li>
</ul></li>
<li class="expanded"><a href="../basic-search/divisions.html" title="">Offices</a><ul><li class="first leaf"><a href="../daltcp/home.htm">Disability, Aging, and Long-Term Care Policy</a></li>
<li class="leaf"><a href="../node/57001.html">Health Policy</a></li>
<li class="leaf"><a href="../hsp/index.shtml.html">Human Services Policy</a></li>
<li class="last leaf"><a href="../node/57011.html">Science and Data Policy</a></li>
</ul></li>
<li class="leaf"><a href="../node/83096.html" title="Strategic Planning">Strategic Planning</a></li>
<li class="last leaf"><a href="../node/83911.html" title="">Contact ASPE</a></li>
</ul></li>
<li class="expanded"><a href="../basic-search/topics.html" title="">Topics</a><ul><li class="first leaf"><a href="../health/reports/2012/ACA-Research/index.cfm.html">Affordable Care Act Research</a></li>
<li class="leaf"><a href="../node/101296.html">Alzheimer&#039;s / Dementia</a></li>
<li class="leaf"><a href="../node/105551.html">Early Childhood</a></li>
<li class="leaf"><a href="../node/103281.html">Incarceration &amp; Reentry</a></li>
<li class="leaf"><a href="../node/83056.html" title="Opioids">Opioids</a></li>
<li class="leaf"><a href="../node/83296.html">Patient-Centered Outcomes Research Trust Fund (PCORTF)</a></li>
<li class="expanded"><a href="../basic-search/poverty.html" title="">Poverty</a><ul><li class="first leaf"><a href="../node/107166.html">Poverty Guidelines</a></li>
<li class="last leaf"><a href="../node/107171.html">Poverty Analysis</a></li>
</ul></li>
<li class="leaf"><a href="../node/164501.html">Teen Pregnancy Prevention</a></li>
<li class="leaf"><a href="../node/100556.html">Homelessness</a></li>
<li class="last leaf"><a href="../node/117441.html">MACRA</a></li>
</ul></li>
<li class="leaf"><a href="../reports.html" title="">Publications</a></li>
<li class="last expanded"><a href="../basic-search/datasets.html" title="">Data and Tools</a><ul><li class="first last leaf"><a href="../pic/index.cfm.html" title="">Evaluation Database</a></li>
</ul></li>
            </ul>
        </div>
    </nav>
    <!-- Navigation / End -->
</header>  <div class="main" role="main">
    <!--PAGEWATCH CODE="USHHS_458"-->
    <section class="page-heading">
  <div class="container">
    <div class="row">

        <div class="col-md-6">
                <h1>

          National Estimates of Prescription Drug Utilization and Expenditures in Long-Term Care Facilities        </h1>
                                 <p class="author">
                                                 <span class="date-display-single" property="dc:date" datatype="xsd:dateTime" content="2006-10-25T00:00:00-04:00">10/25/2006</span>
                           </p>


                  </div>


        <div class="col-md-6">
           <ul class="breadcrumb"><li class="first"><a href="../images/exit_disclaimer.jpg.html" title="Home">Home</a></li>
<li class="last">National Estimates of Prescrip...</li>
</ul>        </div>


    </div>
  </div>
</section>

      <div  class="nd-region nd-region-filter">




      <div  id="Filter" class="row">


















      </div>



      </div>



      <div  class="nd-region nd-region-similar-content">




      <div  id="Similar-Content" class="row">




                                    <div  id="top" class="">

                              <div id="block-views-2100ccfdd214bdbcf634d7e4832c265b" class="widget block block-views solr-similar-content" >

        <div class="title-accent">
			<h3 class = "widget-title" ><span>Similar</span> content</h3>
		</div>

  <div class="view view-similar-content-solr view-id-similar_content_solr view-display-id-block_solr_similar_content view-dom-id-a9ab975ead67554b486531d7c9937983">





    <span class="field-content"><a href="../execsum/prescription-drug-spending-medicare-beneficiaries-institutional-and-residential-settings-1998-2001.html">Prescription Drug Spending by Medicare Beneficiaries in Institutional and Residential Settings, 1998-2001</a></span>
    <span class="field-content"><a href="https://aspe.hhs.gov/basic-report/national-comparison-prescription-drug-expenditures-medicare-beneficiaries-living-community-and-long-term-care-facility-settings">A National Comparison of Prescription Drug Expenditures by Medicare Beneficiaries Living in the Community and Long-Term Care Facility Settings</a></span>
    <span class="field-content"><a href="https://aspe.hhs.gov/basic-report/prescription-drug-spending-medicare-beneficiaries-institutional-and-residential-settings-1998-2001">Prescription Drug Spending by Medicare Beneficiaries in Institutional and Residential Settings, 1998-2001</a></span>
    <span class="field-content"><a href="drug-use-and-spending-medicare-beneficiaries-during-part-qualifying-skilled-nursing-facility-stays-and-non-qualifying-long-term-care-facility-stays.html">Drug Use and Spending for Medicare Beneficiaries During Part A Qualifying Skilled Nursing Facility Stays and Non-Qualifying Long-Term Care Facility Stays</a></span>
    <span class="field-content"><a href="../pdf-report/national-comparison-prescription-drug-expenditures-medicare-beneficiaries-living-community-and-long-term-care-facility-settings.html">A National Comparison of Prescription Drug Expenditures by Medicare Beneficiaries Living in the Community and Long-Term Care Facility Settings</a></span>





</div>
  </div> <!-- /.block -->

                          </div>














      </div>



      </div>



      <div  class="nd-region">



          <div class = "container">

      <div  class="row" id="Content">








                                    <div  class="col-md-12 " id="content">

                              <div id="block-aspe-aspe-addthis" class="widget block block-aspe" >


  <div class="clearfix">
  <ul class="addthis_sharing_toolbox node-share__links" data-url="https://aspe.hhs.gov/basic-report/national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities" data-title="National Estimates of Prescription Drug Utilization and Expenditures in Long-Term Care Facilities">
    <li><a class="addthis_button_print"><img src="../sites/all/themes/stability/stability_aspe/images/print-white.png" alt="print" /></a></li>
    <li><a class="addthis_button_email"><img src="../sites/all/themes/stability/stability_aspe/images/mail-white.png" alt="email" /></a></li>
    <li><a class="addthis_button_twitter"><img src="../sites/all/themes/stability/stability_aspe/images/tw.png" alt="twitter" /></a></li>
<!--    <li><a class="addthis_button_facebook">--><!--</a></li>-->
    <li><a class="addthis_button_compact"><img src="../sites/all/themes/stability/stability_aspe/images/plus-white.png" alt="compact" /></a></li>
  </ul>
</div>

  </div> <!-- /.block -->




  <div class="content clearfix node-basic-report">
    <p><font><b><font face="Calisto MT">U.S. Department of Health and Human Services</font></b></font></p>
<h1>National Estimates of Prescription Drug Utilization and  		Expenditures in Long-Term Care Facilities</h1>
<h3>Linda Simoni-Wastila, PhD, Thomas Shaffer, MHS and Bruce Stuart,  		PhD</h3>
<h3>University of Maryland, Baltimore, Peter Lamy Center on Drug Therapy  		and Aging</h3>
<h3>October 25, 2006</h3>
<p><a href="https://s3-sa-east-1.amazonaws.com/ea-web-scrapes/aspe.hhs.gov/system/files/pdf/75056/pdnatest.pdf">PDF Version</a> (23 PDF  		pages)</p>
<hr /><blockquote>
<p><i>This report was prepared under contract #HHS-100-03-0025 between  		  the U.S. Department of Health and Human Services (HHS), Office of Disability,  		  Aging and Long-Term Care Policy (DALTCP) and the University of Maryland. For  		  additional information about this subject, you can visit the DALTCP home page  		  at <a href="../_/office_specific/daltcp.cfm.html">http://aspe.hhs.gov/_/office_specific/daltcp.cfm</a> or contact the office at  		  HHS/ASPE/DALTCP, Room 424E, H.H. Humphrey Building, 200 Independence Avenue,  		  S.W., Washington, D.C. 20201. The e-mail address is: <a href="mailto:webmaster.DALTCP@HHS.GOV">webmaster.DALTCP@HHS.GOV</a>.  		  The Project Officer was Linda Bergofsky.</i></p>
<p><i>The opinions expressed herein are solely those of the authors and  		  do not reflect the position or policy of any office of the Assistant Secretary  		  for Planning and Evaluation at the U.S. Department of Health and Human Services  		  or any other government authority.</i></p>
</blockquote>
<hr /><h2>TABLE OF CONTENTS</h2>
<dl><dt>I. <a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#intro">INTRODUCTION</a></dt>
<dd>Methods</dd>
<dd>Drug Use Measures</dd>
<dd>Medicare Eligibility and Payor Source</dd>
<dd>Findings</dd>
</dl><dl><dt>II. <a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#use">PRESCRIPTION DRUG UTILIZATION AND EXPENDITURES  		  AMONG MEDICARE BENEFICIARIES RESIDING IN LTCFS, 2001</a></dt>
<dd>Description of the 2001 LTCF Population</dd>
<dd>Prescription Drug Utilization and Expenditures, 2001</dd>
</dl><dl><dt>III. <a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#trend">TRENDS IN ACTUAL AND PROJECTED PRESCRIPTION  		  DRUG SPENDING, 1998-2005</a></dt>
<dd>Discussion</dd>
<dd>Conclusions</dd>
</dl><dl><dt><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#rptlist">LIST OF REPORTS</a></dt>
</dl><dl><dt><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#notes">NOTES</a></dt>
</dl><dl><dt>LIST OF FIGURES</dt>
<dd><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#figure1">FIGURE 1</a>: Total LTCF Prescription Drug  		  Spending by Top 10 Therapeutic Categories, 2001</dd>
<dd><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#figure2">FIGURE 2</a>: Trends in LTCF Population,  		  1998-2001</dd>
<dd><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#figure3">FIGURE 3</a>: Trends in Proportion of LTCF  		  Medicare Beneficiaries Eligible by SSDI Eligibility, 1998-2001</dd>
<dd><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#figure4">FIGURE 4</a>: Mean Annual Growth in Prescription  		  Drug Expenditures in LTCFs, by Facility Type</dd>
<dd><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#figure5">FIGURE 5</a>: Prescription Drug Expenditures by  		  Therapeutic Class, 1998-2001</dd>
<dd><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#figure6">FIGURE 6</a>: Actual and Projected Prescription  		  Drug Spending, 1998-2005</dd>
</dl><dl><dt>LIST OF TABLES</dt>
<dd><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table1">TABLE 1</a>: Stability of Individual Residence by  		  Facility Type, 1998-2001</dd>
<dd><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table2">TABLE 2</a>: Characteristics of Institutionalized  		  Medicare Beneficiaries by Facility Type, 2001</dd>
<dd><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table3">TABLE 3</a>: Prescription Drug Utilization and  		  Expenditures, Overall and by Facility Type, 2001</dd>
<dd><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table4">TABLE 4</a>: Top 10 Most Frequently Utilized  		  Prescription Drug Categories, 2001</dd>
<dd><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table5">TABLE 5</a>: Prescription Drug Spending by  		  Eligibility Status, 2001</dd>
<dd><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table6">TABLE 6</a>: Total and Per User Prescription Drug  		  Spending by Coverage Source, 2001</dd>
<dd><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table7">TABLE 7</a>: Per User Expenditures and Total  		  Expenditures Ranking by Top 5 Therapeutic Categories and by Coverage Source,  		  2001</dd>
<dd><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table8">TABLE 8</a>: Actual and Projected Prescription Drug  		  Expenditures, 1998-2005</dd>
</dl><h2><a name="intro" id="intro">I. INTRODUCTION</a></h2>
<p>Although several studies have provided national estimates of  		prescription drug use by Medicare beneficiaries residing in nursing homes (NHs)  		and other long-term care facilities (LTCFs),<sup><font><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#note1">1</a></font></sup> there are no published estimates of  		expenditures for prescription medications administered in LTCFs in the United  		States. This Policy Brief offers an updated look at prescription drug  		utilization by Medicare beneficiaries residing in LTCFs and reports, for the  		first time, national estimates of prescription drug spending by this  		population. For this paper, LTCFs exclude Medicare-qualified skilled nursing  		facility (SNF) stays unless they lead to a longer stay, as well as exclude  		facilities that do not provide continuous nursing care and have centralized  		medication management. Although findings from this analysis are important to  		many individuals, this particular brief is targeted to policy-makers and payors  		who want to better understand the magnitude of prescription medication spending  		and the drivers of such spending in LTCF. </p>
<p>We focus on two factors thought to influence drug utilization and  		expenditures -- Medicare eligibility status and coverage source. We expect to  		see differences in prescription drug use and spending patterns between  		individuals who are Medicare-eligible on the basis of Social Security  		Disability Insurance (SSDI) versus those who are eligible on the basis of age  		(over 65). Such differences are likely due to the heterogeneity of the two  		populations in terms of disease burden, severity-of-illness, and the types of  		prescription medications required to treat their medical conditions. Medicare  		beneficiaries with different insurance coverage also may exhibit different  		prescription drug utilization and spending patterns, with individuals  		possessing insurance with drug coverage (i.e., Medicaid or private) likely to  		use more and different prescription medications than those with no or typically  		less generous coverage (i.e., Medicare-only covered coverage).</p>
<p>Findings presented here are part of a larger Office of the Assistant  		Secretary for Planning and Evaluation-funded study whose primary purpose is to  		provide updated, detailed spending data on prescription medication use in  		LTCFs. These data will support further analyses of relationships and  		associations detected by these preliminary and descriptive findings presented  		in this and subsequent briefs. The first study aim of this project -- and the  		focus of this brief -- is to produce national estimates of prescription  		utilization and spending in LTCFs for the period 1998-2001. </p>
<p>We provide a detailed snapshot of prescription drug use and spending in  		2001, the latest year for which complete data are available. For this analysis,  		we present summary findings of:</p>
<ul><li>Characteristics of Medicare beneficiaries residing in LTCFs, overall  		  and by facility type.</li>
<li>Total and percent of utilization of prescription drugs by Medicare  		  beneficiaries residing in LTCFs, overall and by facility type.</li>
<li>Total and per user expenditures of prescription drugs by Medicare  		  beneficiaries, overall and by facility type.</li>
<li>Comparison of prescription drug spending by Medicare beneficiaries by  		  eligibility status (SSDI-eligible less than 65 and aged 65 and older).</li>
<li>Comparison of prescription drug use and spending by Medicare  		  beneficiaries by four payor sources -- Medicaid, private prescription with drug  		  coverage, no drug coverage supplementation, and all other coverage with drug  		  coverage status unknown.</li>
</ul><p>A second analysis focuses on total LTCF prescription drug utilization  		and spending trends from 1998-2001, overall, and by therapeutic category. Using  		linear and non-linear projection approaches, we project spending through  		2005.</p>
<h3>Methods</h3>
<p><b><i>Data</i></b>. Data used for this analysis include the 1998-2001  		Medicare Current Beneficiary Survey (MCBS) Cost and Use data. The MCBS is the  		only longitudinal data publicly available to examine prescription drug  		utilization at the individual drug level in the Medicare long-term care  		population. We extracted information on socio-demographics, facility type, and  		payor source from the public-use Cost and Use files. We obtained detailed  		information on prescription drug administration from the Institutional Drug  		Administration (IDA) file. Prescription drug information was obtained from data  		extracted from the Medication Administration Records on prescription drug use  		in LTCFs and collected by MCBS surveyors. This file, known as the IDA, is  		collected at the time of the general MCBS survey and then prepared as an  		analytic file by the University of Maryland under contract to the Centers for  		Medicare and Medicaid Services (CMS). This file is not part of the general MCBS  		survey at this time. More information on the MCBS is available online at:  		<a href="http://www.cms.hhs.gov/MCBS/">http://www.cms.hhs.gov/MCBS/</a>.</p>
<p>A key feature of this particular study was the assignment of a price to  		each prescription drug record. The pricing of drug data is normally based upon  		the presence of a National Drug Code that uniquely identifies important  		characteristics of the drug (e.g., strength, form, and manufacturer) allowing  		it to be individually priced. The MCBS survey, however, does not collect this  		unique identifier for its respondents; rather, drug name, dosage form,  		strength, and several other drug attributes are collected. Pricing of drugs for  		surveyed persons in long-term care settings was done by using the same  		algorithm used by CMS to price drugs for people in the community. This analysis  		represents the first time the CMS drug pricing algorithm has been applied to  		long-term care drug administration data.<sup><font><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#note2">2</a></font></sup> The algorithm takes into account such factors  		as dosage form and strength (among other things) to produce a base price. Once  		a base price is produced, it is further adjusted to reflect the influence of  		payor source to account for various real-world market factors such as discounts  		and dispensing fees.</p>
<h3>Drug Use Measures</h3>
<p>The measures of prescription drug utilization include: total annual  		users; annual administrations; mean annual administrations per user; and mean  		monthly administrations per user. The measures of expenditures include: total  		annual expenditures; annual mean expenditures per beneficiary; and mean monthly  		expenditures per user. Prescription drug use and spending are examined in  		aggregate, as well as by therapeutic category. All use and spending measures  		are weighted to provide national estimates. All expenditures are presented in  		current dollars of the year analyzed. It is important to note estimates  		reported here only include prescription drugs used in LTCFs. The pricing  		algorithm specifically excludes the pricing of over the counter (OTC) drugs;  		thus, they have been excluded from these analyses. Although OTC medications  		represent a significant component of medication utilization, accounting for  		almost a third of all administrations, they are comparatively inexpensive due  		to their OTC status.<sup><font><a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#note3">3</a></font></sup></p>
<h3>Medicare Eligibility and Payor Source</h3>
<p>We consider prescription drug utilization and expenditures in the  		context of two primary variables: Medicare eligibility and source of payor  		source. For this analysis, we considered all individuals who qualify as  		SSDI-eligible (i.e., less than 65 years of age) to be Medicare-eligible on the  		basis of disability and all individuals aged 65 and older to be  		Medicare-eligible on the basis of age. </p>
<p>Payor source reflects the health insurance source for the individual  		during the year as determined by the MCBS which tracks coverage on a  		month-by-month basis. Supplemental payor source is assigned based on a  		four-part hierarchy of coverage scenarios of traditional Medicaid (i.e.,  		Medicaid programs which provide drug coverage as opposed to waiver programs  		without drug coverage), private coverage with prescription drug coverage, all  		other payor source with unknown Rx coverage, and no supplemental coverage  		(i.e., Medicare-only). For this analysis, any evidence of Medicaid coverage was  		given precedence over all other forms of coverage, followed by private  		insurance with evidence of prescription drug coverage, and then all other forms  		of supplemental coverage with no identifiable source of insurance. Individuals  		with no source of supplemental coverage lack any evidence of other supplemental  		coverage and thus are assumed to have Medicare as their sole source of health  		coverage. It is important to note that this paper uses data that precedes the  		implementation of the Part D provisions of the Medicare Prescription Drug,  		Improvement, and Modernization Act of 2005 (MMA).</p>
<p><b><i>Residential setting</i></b>. LTCFs were stratified by the internal  		designation of the facility according to the MCBS. The facility types used were  		Nursing Home, Assisted Living and All Other facilities. Non-qualifying stays in  		SNFs after a qualifying three-day post-acute hospitalization are not considered  		as a long-term NH stay; instead, they are categorized in the All Other  		facilities. Assisted Living Facilities (ALFs) includes those facilities  		designated as assisted living by the survey and do not include other types of  		congregate care settings. Thus, NH and ALF represent single homogenous facility  		type designations. All Other Facilities (OFs) include rehabilitation,  		psychiatric, group homes, congregate care, bed and board, Mental Retardation  		and Developmental Disability (MRDD) residences, short-term SNF stays  		post-hospitalization, and others.</p>
<p>The MCBS offers the ability to establish residence in a specific  		facility type during a period of time. Because individuals can reside in more  		than one facility during the year, this presented a methodological challenge in  		allocating prescription medication utilization and expenditures to facility  		type. For this brief, prescription medications were assigned to the setting the  		respondent was determined to be in for the month of prescription. For months  		where the respondent moved between several long-term settings a systematic  		approach was used to resolve the most likely setting to assign.</p>
<p>In general, there is considerable stability across facility types (since  		residents tend to stay where they are) and across the study years. Residents in  		NH show the highest degree of stability (ranging from 88-91% of residents who  		remain in just that setting), followed by ALF (range 76-86%), with residents of  		OF settings showing the highest degree of mobility across settings (<a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table1">Table 1</a>).</p>
<table><tr><td colspan="5"><font><b><a name="table1" id="table1">TABLE 1</a>. Stability of Individual  			 Residence by Facility Type, 1998-2001</b></font></td>
</tr><tr><td scope="col"><font><b> </b></font></td>
<td scope="col"><font><b>1998</b></font></td>
<td scope="col"><font><b>1999</b></font></td>
<td scope="col"><font><b>2000</b></font></td>
<td scope="col"><font><b>2001</b></font></td>
</tr><tr><td scope="row"><font>% NH  			 residents solely in a NH setting (N=1,832,837)</font></td>
<td><font>  90.9%  </font></td>
<td><font>  88.4%  </font></td>
<td><font>  87.4%  </font></td>
<td><font>  87.7%  </font></td>
</tr><tr><td scope="row"><font>% ALF  			 residents solely in an ALF setting (N=287,566)</font></td>
<td><font>85.9%</font></td>
<td><font>82.0%</font></td>
<td><font>72.5%</font></td>
<td><font>76.6%</font></td>
</tr><tr><td scope="row"><font>% Other  			 residents solely in OF settings (N=839,532)</font></td>
<td><font>76.2%</font></td>
<td><font>72.6%</font></td>
<td><font>67.6%</font></td>
<td><font>71.6%</font></td>
</tr><tr><td scope="row"><font>% of  			 residents across all settings who remain in just 1  			 setting  </font></td>
<td><font>93.1%</font></td>
<td><font>91.1%</font></td>
<td><font>89.3%</font></td>
<td><font>90.5%</font></td>
</tr><tr><td colspan="5"><font><b>SOURCE</b>: MCBS, 1998-2001.</font></td>
</tr></table><h3>Findings</h3>
<p>The following results are grouped into two sections: <a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#use">Section II</a> examines prescription drug utilization and  		expenditures in 2001, the latest year for which expenditures data are available  		for the LTCF population. <a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#trend">Section III</a> examines trends in  		prescription drug spending and characterizes changes in the LTCF population  		from 1998-2001. Based on spending from 1998-2001, we present projected  		prescription drug spending through 2005. These estimates are current dollars  		and are not constant dollars adjusted for growth in spending.</p>
<h2><a name="use" id="use">II. PRESCRIPTION DRUG UTILIZATION AND EXPENDITURES AMONG  		MEDICARE BENEFICIARIES RESIDING IN LTCFS, 2001</a></h2>
<h3>Description of the 2001 LTCF Population</h3>
<p>In 2001, nearly 2.7 million Medicare beneficiaries resided for at least  		part of the year in one or more LTCFs. Of these, 68.3%, or 1.8 million Medicare  		beneficiaries, spent at least one month in a NH (<a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table2">Table  		2</a>), 287,000 spent at least one month in an ALF, and 839,000 spent at least  		one month in some other institutional facility. As noted above, there is  		considerable stability in the LTCF population in 2001 -- 90.5% of all  		beneficiaries spent the entire year in just one facility type, while the  		remaining 9.5% transitioned between facility types (<a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table1">Table  		1</a>). Thus, in 2001, of the entire LTCF population, 59.9% resided only in a  		NH, 8.2% only resided in an ALF, and 22.4% only resided in another facility  		type (data not shown).</p>
<table><tr><td colspan="6"><font><b><a name="table2" id="table2">TABLE 2</a>. Characteristics of  			 Institutionalized Medicare Beneficiaries by Facility Type, 2001</b></font></td>
</tr><tr><td rowspan="2" scope="col"><font><b> </b></font></td>
<td colspan="2" scope="col"><font><b>Total  			 Facility(N=2,684,426)</b></font></td>
<td scope="col"><font><b>Nursing Home(N=1,832,837)</b></font></td>
<td scope="col"><font><b>Assisted Living Facility(N=287,566)  			 </b></font></td>
<td scope="col"><font><b>Other Facilities(N=839,532)</b></font></td>
</tr><tr><td scope="col"><font><b>  Frequency  </b></font></td>
<td scope="col"><font><b>  As %  </b></font></td>
<td scope="col"><font><b>  As %  </b></font></td>
<td scope="col"><font><b>  As %  </b></font></td>
<td scope="col"><font><b>  As %  </b></font></td>
</tr><tr><td scope="row"><font>Under  			 65</font></td>
<td><font>435,596</font></td>
<td><font>16.2</font></td>
<td><font>9.4</font></td>
<td><font>5.4++</font></td>
<td><font>32.4</font></td>
</tr><tr><td scope="row"><font>65 - 74  			 years</font></td>
<td><font>306,347</font></td>
<td><font>11.4</font></td>
<td><font>12.1</font></td>
<td><font>15.0</font></td>
<td><font>9.8</font></td>
</tr><tr><td scope="row"><font>74 - 85  			 years</font></td>
<td><font>809,008</font></td>
<td><font>30.1</font></td>
<td><font>34.0</font></td>
<td><font>24.7</font></td>
<td><font>23.3</font></td>
</tr><tr><td scope="row"><font>85+  			 years</font></td>
<td><font>  1,133,475  </font></td>
<td><font>42.2</font></td>
<td><font>44.5</font></td>
<td><font>54.9</font></td>
<td><font>34.5</font></td>
</tr><tr><td colspan="6"><font> </font></td>
</tr><tr><td scope="row"><font>Male</font></td>
<td><font>908,736</font></td>
<td><font>33.9</font></td>
<td><font>31.5</font></td>
<td><font>24.0</font></td>
<td><font>41.2</font></td>
</tr><tr><td scope="row"><font>Female</font></td>
<td><font>1,775,691</font></td>
<td><font>66.1</font></td>
<td><font>68.5</font></td>
<td><font>76.0</font></td>
<td><font>58.8</font></td>
</tr><tr><td colspan="6"><font> </font></td>
</tr><tr><td scope="row"><font>White</font></td>
<td><font>2,373,192</font></td>
<td><font>88.4</font></td>
<td><font>86.1</font></td>
<td><font>96.8</font></td>
<td><font>91.1</font></td>
</tr><tr><td scope="row"><font>Non-White</font></td>
<td><font>311,235</font></td>
<td><font>11.6</font></td>
<td><font>13.9</font></td>
<td><font>3.2++</font></td>
<td><font>8.9</font></td>
</tr><tr><td colspan="6"><font> </font></td>
</tr><tr><td scope="row"><font>Married</font></td>
<td><font>524,805</font></td>
<td><font>19.5</font></td>
<td><font>20.7</font></td>
<td><font>22.7</font></td>
<td><font>14.3</font></td>
</tr><tr><td scope="row"><font>Widowed</font></td>
<td><font>1,357,800</font></td>
<td><font>50.6</font></td>
<td><font>54.7</font></td>
<td><font>59.9</font></td>
<td><font>40.1</font></td>
</tr><tr><td scope="row"><font>Single</font></td>
<td><font>801,821</font></td>
<td><font>29.9</font></td>
<td><font>24.6</font></td>
<td><font>17.4</font></td>
<td><font>45.6</font></td>
</tr><tr><td colspan="6"><font> </font></td>
</tr><tr><td scope="row"><font>&lt;HS</font></td>
<td><font>1,494,703</font></td>
<td><font>55.7</font></td>
<td><font>55.9</font></td>
<td><font>45.3</font></td>
<td><font>57.4</font></td>
</tr><tr><td scope="row"><font>High  			 School</font></td>
<td><font>609,704</font></td>
<td><font>22.7</font></td>
<td><font>23.7</font></td>
<td><font>23.1</font></td>
<td><font>18.8</font></td>
</tr><tr><td scope="row"><font>Some  			 College</font></td>
<td><font>580,020</font></td>
<td><font>21.6</font></td>
<td><font>20.4</font></td>
<td><font>31.6</font></td>
<td><font>23.8</font></td>
</tr><tr><td scope="row" colspan="6"><font> </font></td>
</tr><tr><td scope="row"><font>East</font></td>
<td><font>594,076</font></td>
<td><font>22.1</font></td>
<td><font>21.0</font></td>
<td><font>12.5++</font></td>
<td><font>27.7</font></td>
</tr><tr><td scope="row"><font>Midwest</font></td>
<td><font>737,073</font></td>
<td><font>27.5</font></td>
<td><font>28.9</font></td>
<td><font>28.4</font></td>
<td><font>23.6</font></td>
</tr><tr><td scope="row"><font>South</font></td>
<td><font>880,043</font></td>
<td><font>32.8</font></td>
<td><font>35.6</font></td>
<td><font>31.7</font></td>
<td><font>24.7</font></td>
</tr><tr><td scope="row"><font>West</font></td>
<td><font>473,234</font></td>
<td><font>17.6</font></td>
<td><font>14.6</font></td>
<td><font>27.4</font></td>
<td><font>24.0</font></td>
</tr><tr><td colspan="6"><font> </font></td>
</tr><tr><td scope="row"><font>Metro</font></td>
<td><font>2,045,585</font></td>
<td><font>76.2</font></td>
<td><font>74.6</font></td>
<td><font>87.2</font></td>
<td><font>79.1</font></td>
</tr><tr><td scope="row"><font>Non-Metro</font></td>
<td><font>638,841</font></td>
<td><font>23.8</font></td>
<td><font>25.4</font></td>
<td><font>12.8</font></td>
<td><font>20.9</font></td>
</tr><tr><td colspan="6"><font> </font></td>
</tr><tr><td scope="row"><font>Meets FPL for  			 2001</font></td>
<td><font>901,295</font></td>
<td><font>33.6</font></td>
<td><font>35.3</font></td>
<td><font>14.9</font></td>
<td><font>31.8</font></td>
</tr><tr><td scope="row"><font>100-200%  			 above FPL</font></td>
<td><font>1,032,625</font></td>
<td><font>38.5</font></td>
<td><font>38.3</font></td>
<td><font>42.5</font></td>
<td><font>38.0</font></td>
</tr><tr><td scope="row"><font>200-300%  			 above FPL</font></td>
<td><font>356,010</font></td>
<td><font>13.3</font></td>
<td><font>13.0</font></td>
<td><font>15.7</font></td>
<td><font>15.9</font></td>
</tr><tr><td scope="row"><font>&gt;3x above  			 FPL</font></td>
<td><font>394,496</font></td>
<td><font>14.7</font></td>
<td><font>13.4</font></td>
<td><font>26.9</font></td>
<td><font>14.3</font></td>
</tr><tr><td colspan="6"><font> </font></td>
</tr><tr><td scope="row"><font>Traditional  			 Medicaid</font></td>
<td><font>1,670,518</font></td>
<td><font>62.2</font></td>
<td><font>68.3</font></td>
<td><font>16.5</font></td>
<td><font>57.1</font></td>
</tr><tr><td scope="row"><font>Private, Rx  			 Coverage</font></td>
<td><font>261,570</font></td>
<td><font>9.7</font></td>
<td><font>8.5</font></td>
<td><font>19.3</font></td>
<td><font>13.6</font></td>
</tr><tr><td scope="row"><font>No  			 Supplementation</font></td>
<td><font>282,414</font></td>
<td><font>10.5</font></td>
<td><font>9.1</font></td>
<td><font>21.8</font></td>
<td><font>9.5</font></td>
</tr><tr><td scope="row"><font>All Others,  			 Rx Cov unknown</font></td>
<td><font>469,924</font></td>
<td><font>17.5</font></td>
<td><font>14.1</font></td>
<td><font>42.5</font></td>
<td><font>19.8</font></td>
</tr><tr><td colspan="6"><font> </font></td>
</tr><tr><td scope="row"><font>Excellent +  			 Very Good</font></td>
<td><font>305,653</font></td>
<td><font>13.0</font></td>
<td><font>8.3</font></td>
<td><font>22.3</font></td>
<td><font>19.2</font></td>
</tr><tr><td scope="row"><font>Good</font></td>
<td><font>648,359</font></td>
<td><font>27.5</font></td>
<td><font>23.8</font></td>
<td><font>42.8</font></td>
<td><font>31.2</font></td>
</tr><tr><td scope="row"><font>Fair</font></td>
<td><font>942,763</font></td>
<td><font>40.0</font></td>
<td><font>45.3</font></td>
<td><font>21.8</font></td>
<td><font>32.2</font></td>
</tr><tr><td scope="row"><font>Poor</font></td>
<td><font>450,234</font></td>
<td><font>19.1</font></td>
<td><font>22.1</font></td>
<td><font>12.4</font></td>
<td><font>16.9</font></td>
</tr><tr><td scope="row"><font>Missing</font></td>
<td><font>9,124</font></td>
<td><font>0.4++</font></td>
<td><font>0.5++</font></td>
<td><font>0.7++</font></td>
<td><font>0.5++</font></td>
</tr><tr><td colspan="6"><font> </font></td>
</tr><tr><td scope="row"><font>No ADL  			 dependencies</font></td>
<td><font>272,361</font></td>
<td><font>11.5</font></td>
<td><font>6.2</font></td>
<td><font>20.9</font></td>
<td><font>19.5</font></td>
</tr><tr><td scope="row"><font>1 - 2 ADL  			 dependencies</font></td>
<td><font>420,239</font></td>
<td><font>17.7</font></td>
<td><font>14.2</font></td>
<td><font>27.6</font></td>
<td><font>20.1</font></td>
</tr><tr><td scope="row"><font>3 - 4  			 dependencies</font></td>
<td><font>436,464</font></td>
<td><font>18.4</font></td>
<td><font>18.2</font></td>
<td><font>20.0</font></td>
<td><font>20.2</font></td>
</tr><tr><td scope="row"><font>5 - 6  			 dependencies</font></td>
<td><font>1,246,211</font></td>
<td><font>52.5</font></td>
<td><font>61.4</font></td>
<td><font>31.4</font></td>
<td><font>40.3</font></td>
</tr><tr><td colspan="6"><font><b>SOURCE</b>: MCBS, 2001. * Other Facility includes:  			 congregate care settings, MRDD and rehabilitation settings, psychiatric  			 institutions, and group homes. ++ Estimates considered unreliable due top  			 RSE &gt;30.</font></td>
</tr></table><p>The preponderance of beneficiaries residing in LTCF facilities were 85  		years and older (42.2%), although this varied by facility type. Although  		disabled beneficiaries comprised 16.2% of the entire LTCF population, nearly  		one-third (32.4%) of OF residents were SSDI-eligible. One-third (33.9%) of LTCF  		Medicare beneficiaries are male, nearly one-fifth (19.5%) are married, more  		than half (55.7%) did not complete high school, and three-quarters (76.2%)  		resided in facilities located in metropolitan areas. </p>
<p>One-third (33.6%) of Medicare beneficiaries residing in LTCFs have  		incomes at or below the Federal Poverty Level (FPL) and 38.5% are within  		100-200% of the FPL. Fewer ALF beneficiaries meet FPL income criteria. Medicaid  		is the most common payor source of health coverage, with 62.2% of all Medicare  		LTCF residents having Medicaid coverage, 9.7% possessing private insurance with  		prescription drug benefits, and 17.5% possessing coverage, including Medicaid  		waiver programs, with unknown or uncertain prescription drug benefits. More  		than one in ten (10.5%) Medicare beneficiaries in 2001 only possessed Medicare  		coverage. Coverage source varies by facility type --14.9% of ALF residents,  		57.1% of OF residents, and 68.3% of NH residents receive Medicaid coverage.  		Medicare beneficiaries with no other coverage supplementation constituted 21.8%  		of all ALF residents. </p>
<p>More than half (59.1%) of all Medicare LTCF beneficiaries or their  		survey proxies report their health status as poor or fair, with 67.4% of NH  		residents reporting the same. Across all LTCF residents, 11.5% reported no  		limitations in activities of daily living. This proportion was lowest in NH  		residents (6.2%) and highest in ALF residents (20.9%) and OF residents (19.5%).  		</p>
<h3>Prescription Drug Utilization and Expenditures,  		2001</h3>
<p>In 2001, 95.6% of the Medicare LTCF beneficiary population used at least  		one prescription drug (<a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table3">Table 3</a>). There was little  		variability in any prescription drug utilization across facility type, ranging  		from 92.2% in OF residents to 98.0% of residents in ALFs. </p>
<table><tr><td colspan="4"><font><b><a name="table3" id="table3">TABLE 3</a>. Prescription Drug Utilization  			 and Expenditures, Overall and by Facility Type, 2001</b></font></td>
</tr><tr><td scope="col"><font><b> </b></font></td>
<td scope="col"><font><b>  % of Facility Population  			 Using  at Least One Prescription Drug</b></font></td>
<td scope="col"><font><b>  Total Annual  			 Expenditures  (in million $)</b></font></td>
<td scope="col"><font><b>Expenditures Per User  (rounded to  			 the nearest $)  </b></font></td>
</tr><tr><td scope="row"><font>Total  			 LTCF</font></td>
<td><font>95.6%</font></td>
<td><font>5,427</font></td>
<td><font>2,110</font></td>
</tr><tr><td scope="row"><font>Nursing  			 Home</font></td>
<td><font>97.4%</font></td>
<td><font>3,482</font></td>
<td><font>1,957</font></td>
</tr><tr><td scope="row"><font>Assisted  			 Living Facilities  </font></td>
<td><font>98.0%</font></td>
<td><font>547</font></td>
<td><font>2,011</font></td>
</tr><tr><td scope="row"><font>All Other  			 Facilities</font></td>
<td><font>92.2%</font></td>
<td><font>1,398</font></td>
<td><font>1,566</font></td>
</tr><tr><td colspan="4"><font><b>SOURCE</b>: MCBS, 2001.</font></td>
</tr></table><p>In 2001, total prescription drug spending for all LTCFs in the United  		States exceeded $5.427 billion (<a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table3">Table 3</a>). The mean annual  		prescription drug expenditures per user of at least one prescription drug was  		$2,110. Prescription drug spending in NHs accounted for 64.1% of total LTCF  		drug spending, followed by OFs (25.8%) and ALFs (10.1%). </p>
<p><b><i>Prescription drug use and spending by therapeutic  		category</i></b>. The Top 10 therapeutic categories and proportion of LTCF  		Medicare residents using them most frequently across all LTCFs in 2001 are  		listed in <a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table4">Table 4</a>. The most commonly used therapeutic  		category was psychotherapeutics, which includes of antidepressants,  		antipsychotics, anxiolytics and other related pharmacologic classes.  		Antibiotics and other anti-infective agents comprise the second most commonly  		used medication category. </p>
<table><tr><td colspan="2"><font><b><a name="table4" id="table4">TABLE 4</a>. Top 10 Most Frequently  			 Utilized Prescription Drug Categories, 2001</b></font></td>
</tr><tr><td scope="col"><font><b>Therapeutic Classification</b></font></td>
<td scope="col"><font><b>% all Facility Residents  Using At  			 Least One Drug  </b></font></td>
</tr><tr><td scope="row"><font>Psychotherapeutics</font></td>
<td><font>61.4%</font></td>
</tr><tr><td scope="row"><font>Anti-infectives</font></td>
<td><font>53.8%</font></td>
</tr><tr><td scope="row"><font>Gastrointestinal agents</font></td>
<td><font>47.2%</font></td>
</tr><tr><td scope="row"><font>Cardiac  			 drugs</font></td>
<td><font>37.5%</font></td>
</tr><tr><td scope="row"><font>Diuretics</font></td>
<td><font>36.8%</font></td>
</tr><tr><td scope="row"><font>Cardiovascular agents</font></td>
<td><font>36.3%</font></td>
</tr><tr><td scope="row"><font>Analgesics</font></td>
<td><font>29.9%</font></td>
</tr><tr><td scope="row"><font>Autonomic  			 agents</font></td>
<td><font>27.2%</font></td>
</tr><tr><td scope="row"><font>Electrolytes</font></td>
<td><font>24.9%</font></td>
</tr><tr><td scope="row"><font>Central  			 nervous system agents  </font></td>
<td><font>22.4%</font></td>
</tr></table><table><tr><td><font><b><a name="figure1" id="figure1">FIGURE 1</a>. Total LTCF  			 Prescription Drug Spending by Top 10 Therapeutic Categories,  			 2001</b></font></td>
</tr><tr><td><img src="https://aspe.hhs.gov/system/files/images-reports-basic/68951/pdnatest-fig1.JPG" alt="bar chart: total LTCF prescription drug spending by top 10 therapeutic categories, 2001" /></td>
</tr></table><p>The Top 10 spending therapeutic categories accounted for 75.4% of total  		prescription drug spending in LTCFs in 2001 (<a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#figure1">Figure 1</a>).  		Psychotherapeutic agents accounted for $1.426 billion, or 26.3% of total  		prescription drug spending, in 2001. The second most expensive therapeutic  		category was gastrointestinal agents, account for $684 million, or 12.6% of  		total prescription drug spending. Together, the psychotherapeutic and  		gastrointestinal drug categories accounted for nearly $4 in every $10 dollars  		spent on prescription drugs in LTCFs. </p>
<p>The use of and spending on these two broad drug categories is not  		surprising -- psychotherapeutics and gastrointestinal drugs are used to treat  		medical and health conditions commonly found among LTCF residents, including  		depression, anxiety, sleep disorders, schizophrenia, agitation and problems  		associated with dementia and delirium, ulcerative disease, constipation, and  		diarrhea. The remaining eight therapeutic classes, ranked in order of spending,  		include: autonomic, cardiovascular, central nervous system, cardiac,  		anti-infectives, anti-arthritics, blood modifiers, and hormones.</p>
<p>There was little variation in the therapeutic categories comprising the  		most expensive Top 10 therapeutic categories across facility type.  		Psychotherapeutic and gastrointestinal agents accounted for the first and  		second most expensive therapeutic category across all facility types. Seven  		therapeutic categories (autonomic, cardiovascular, central nervous system,  		cardiac, anti-infectives and hormones) all ranked in the Top 10 for all three  		facility settings. Blood modifiers constituted a tenth therapeutic category for  		all facility types except OFs, where hypoglycemic agents took its place. There  		was little uniformity of drug spending patterns across facility types for the  		remaining Top 10 therapeutic categories. </p>
<p><b><i>Prescription drug spending by eligibility status, 2001</i></b>. As  		expected, patterns of prescription drug use and spending varied by whether or  		not individuals were Medicare SSDI-eligible. Although SSDI-eligible Medicare  		beneficiaries constituted 16.2% of the institutionalized Medicare population,  		their spending on prescription drugs accounted for 18.9% of total prescription  		drug spending. Differences in annual prescription drug spending per user are  		particularly notable, with the SSDI beneficiaries spending more than $800 more  		per year than their aged counterparts (<a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table5">Table 5</a>).</p>
<p>There is also variation in the types of drugs used by SSDI versus aged  		Medicare beneficiaries. Although psychotherapeutic agents was the most  		frequently used therapeutic category by both SSDI and aged beneficiaries, the  		remaining Top 10 therapeutic categories varied by type and ranking (<a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table5">Table 5</a>). Though we found that the proportions of SSDI and  		aged Medicare beneficiaries using at least one psychotherapeutic agent in 2001  		were essentially identical (61.5% versus 61.4%, respectively),  		psychotherapeutic spending was disproportionate. That is, total  		psychotherapeutic spending by SSDI beneficiaries accounted for 41.4% of total  		prescription drug spending, compared to 22.8% by aged. Mean per user  		psychotherapeutic spending also varied, with SSDI Medicare users spending  		$1,680 annually compared to $710 spent by aged Medicare users.</p>
<table><tr><td colspan="6"><font><b><a name="table5" id="table5">TABLE 5</a>. Prescription Drug Spending by  			 Eligibility Status, 2001</b></font></td>
</tr><tr><td colspan="3" scope="col"><font><b>SSDI-Eligible (Under 65)  			 </b></font></td>
<td colspan="3" scope="col"><font><b>Aged (Over 65)</b></font></td>
</tr><tr><td scope="col"><font><b> </b></font></td>
<td scope="col"><font><b>  Total Facility $  (in  			 millions)</b></font></td>
<td scope="col"><font><b>Mean $  Per  			 User  </b></font></td>
<td scope="col"><font><b> </b></font></td>
<td scope="col"><font><b>  Total Facility $  (in  			 millions)</b></font></td>
<td scope="col"><font><b>Mean $  Per  			 User  </b></font></td>
</tr><tr><td scope="row"><font>Psychotherapeutics</font></td>
<td><font>423.9</font></td>
<td><font>1,680</font></td>
<td><font>Psychotherapeutics</font></td>
<td><font>1,001.9</font></td>
<td><font>710</font></td>
</tr><tr><td scope="row"><font>Central  			 Nervous System</font></td>
<td><font>127.2</font></td>
<td><font>783</font></td>
<td><font>Gastrointestinals</font></td>
<td><font>571.5</font></td>
<td><font>510</font></td>
</tr><tr><td scope="row"><font>Gastrointestinals</font></td>
<td><font>112.5</font></td>
<td><font>717</font></td>
<td><font>Autonomic</font></td>
<td><font>326.5</font></td>
<td><font>484</font></td>
</tr><tr><td scope="row"><font>Cardiovascular</font></td>
<td><font>45.3</font></td>
<td><font>465</font></td>
<td><font>Cardiovascular</font></td>
<td><font>301.6</font></td>
<td><font>340</font></td>
</tr><tr><td scope="row"><font>Anti-infectives</font></td>
<td><font>37.5</font></td>
<td><font>215</font></td>
<td><font>Cardiac</font></td>
<td><font>241.7</font></td>
<td><font>250</font></td>
</tr><tr><td scope="row"><font>Autonomic</font></td>
<td><font>21.4</font></td>
<td><font>347</font></td>
<td><font>Anti-infectives</font></td>
<td><font>199.6</font></td>
<td><font>156</font></td>
</tr><tr><td scope="row"><font>Skin  			 Preparations</font></td>
<td><font>18.7</font></td>
<td><font>197</font></td>
<td><font>Anti-arthritics</font></td>
<td><font>179.4</font></td>
<td><font>345</font></td>
</tr><tr><td scope="row"><font>Hypoglycemics</font></td>
<td><font>18.4</font></td>
<td><font>590</font></td>
<td><font>Central Nervous  			 System</font></td>
<td><font>154.6</font></td>
<td><font>352</font></td>
</tr><tr><td scope="row"><font>Analgesics</font></td>
<td><font>17.1</font></td>
<td><font>248</font></td>
<td><font>Blood  			 Modifiers</font></td>
<td><font>149.4</font></td>
<td><font>301</font></td>
</tr><tr><td scope="row"><font>Hormones</font></td>
<td><font>16.1</font></td>
<td><font>285</font></td>
<td><font>Hormones</font></td>
<td><font>143.6</font></td>
<td><font>270</font></td>
</tr><tr><td colspan="6"><font> </font></td>
</tr><tr><td scope="row"><font>All  			 Therapeutic Categories</font></td>
<td><font>1,024.8</font></td>
<td><font>2,811</font></td>
<td><font>All Therapeutic  			 Categories</font></td>
<td><font>4,402.6</font></td>
<td><font>1,983</font></td>
</tr><tr><td scope="row"><font>Total Top 10  			 Spending</font></td>
<td><font>838.1</font></td>
<td><font>--</font></td>
<td><font>Total Top 10  			 Spending</font></td>
<td><font>3,269.8</font></td>
<td><font>--</font></td>
</tr><tr><td scope="row"><font>Top 10  			 Categories as Percent of Total  </font></td>
<td><font>81.8%</font></td>
<td><font>--</font></td>
<td><font>Top 10 Categories as  			 Percent of Total  </font></td>
<td><font>74.3%</font></td>
<td><font>--</font></td>
</tr><tr><td colspan="6"><font><b>SOURCE</b>: MCBS, 2001.</font></td>
</tr></table><p><b><i>Prescription drug spending by payor source, 2001</i></b>. Medicaid  		paid the largest share of prescription drug expenditures in 2001, accounting  		for 65.9%, or $3,572.4 million, of total prescription drug expenditures among  		Medicare beneficiaries residing in LTCFs (<a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table6">Table 6</a>).  		Individuals with no supplemental coverage accounted for $554.2 million in drug  		expenditures, all of which is assumed to be paid for out-of-pocket. </p>
<table><tr><td colspan="3"><font><b><a name="table6" id="table6">TABLE 6</a>. Total and Per User  			 Prescription Drug Spending by Coverage Source, 2001</b></font></td>
</tr><tr><td scope="col"><font><b> </b></font></td>
<td scope="col"><font><b>  Total Spending  ($ in  			 millions)</b></font></td>
<td scope="col"><font><b>Spending Per User  (Rounded to the  			 nearest $)  </b></font></td>
</tr><tr><td scope="row"><font>Medicaid</font></td>
<td><font>3,572.4</font></td>
<td><font>2,237</font></td>
</tr><tr><td scope="row"><font>Private  			 Coverage with Prescription Drug Coverage</font></td>
<td><font>297.7</font></td>
<td><font>1,155</font></td>
</tr><tr><td scope="row"><font>Other  			 Coverage with Prescription Coverage Unknown  </font></td>
<td><font>1,003.0</font></td>
<td><font>2,168</font></td>
</tr><tr><td scope="row"><font>No  			 Supplemental Coverage</font></td>
<td><font>554.2</font></td>
<td><font>2,077</font></td>
</tr><tr><td colspan="3"><font><b>SOURCE</b>: MCBS, 2001.</font></td>
</tr></table><p>There was variability in annual per user prescription drug spending,  		with individuals possessing private coverage with prescription drug spending  		the least ($1,155 per year) and Medicaid-dual eligibles expending the most  		($2,237). Annual expenditures per user for beneficiaries with unknown  		prescription coverage and those with no supplemental coverage also paying  		significant sums on prescription drugs were $2,168 and $2,077 per user,  		respectively.</p>
<p>Psychotherapeutic and gastrointestinal agents remained the top two most  		expensive therapeutic classes, regardless of coverage source (<a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table7">Table 7</a>). Due to the sheer volume of LTCF beneficiaries with  		Medicaid as an coverage source, spending patterns by therapeutic category are  		almost wholly driven by this insurer. In addition to variability in ranking of  		therapeutic category by coverage source, there is also considerable per user  		differences in spending by therapeutic category. For example, annual  		expenditures for psychotherapeutics ranged from $976 for Medicare beneficiaries  		also possessing Medicaid coverage to $364 for those beneficiaries with private  		prescription drug coverage. Medicare beneficiaries without any supplemental  		coverage paid nearly as much for psychotherapeutic agents ($867) and more for  		gastrointestinal agents ($620) than did dual eligibles ($552). </p>
<table><tr><td colspan="6"><font><b><a name="table7" id="table7">TABLE 7</a>. Per User Expenditures and  			 Total Expenditures Ranking by Top 5 Therapeutic Categories and by Coverage  			 Source, 2001</b></font></td>
</tr><tr><td rowspan="2" scope="col"><font><b> </b></font></td>
<td scope="col"><font><b>All CoveragesSources</b></font></td>
<td scope="col"><font><b>Medicaid(N=1,670,518)</b></font></td>
<td scope="col"><font><b>Private  			 InsuranceCoverage(N=261,570)</b></font></td>
<td scope="col"><font><b>Other Insurance withPrescription Coverage  			 Unknown(N=469,924)</b></font></td>
<td scope="col"><font><b>No SupplementalCoverage(N=282,414)  			 </b></font></td>
</tr><tr><td colspan="5" scope="col"><font><b>Per User Expenditures in  			 dollars ($)(Rank in Terms of Total Category Spending)</b></font></td>
</tr><tr><td scope="row"><font>Pyschotherapeutics</font></td>
<td><font>857 (1)</font></td>
<td><font>976 (1)</font></td>
<td><font>364 (1)</font></td>
<td><font>688 (1)</font></td>
<td><font>867 (1)</font></td>
</tr><tr><td scope="row"><font>Gastrointestinals</font></td>
<td><font>535 (2)</font></td>
<td><font>552 (2)</font></td>
<td><font>308 (2)</font></td>
<td><font>548 (2)</font></td>
<td><font>620 (2)</font></td>
</tr><tr><td scope="row"><font>Autonomic</font></td>
<td><font>473 (3)</font></td>
<td><font>467 (5)</font></td>
<td><font>287 (3)</font></td>
<td><font>581 (3)</font></td>
<td><font>537 (3)</font></td>
</tr><tr><td scope="row"><font>Cardiovascular</font></td>
<td><font>352 (4)</font></td>
<td><font>367 (4)</font></td>
<td><font>208 (6)</font></td>
<td><font>393 (4)</font></td>
<td><font>340 (4)</font></td>
</tr><tr><td scope="row"><font>Central  			 Nervous System</font></td>
<td><font>469 (5)</font></td>
<td><font>497 (3)</font></td>
<td><font>202 (12)</font></td>
<td><font>304 (11)</font></td>
<td><font>706 (5)</font></td>
</tr><tr><td scope="row"><font>Cardiac</font></td>
<td><font>252 (6)</font></td>
<td><font>265 (7)</font></td>
<td><font>164 (5)</font></td>
<td><font>271 (6)</font></td>
<td><font>256 (6)</font></td>
</tr><tr><td scope="row"><font>Anti-infectives</font></td>
<td><font>163 (7)</font></td>
<td><font>173 (6)</font></td>
<td><font>216 (4)</font></td>
<td><font>134 (10)</font></td>
<td><font>103 (10)</font></td>
</tr><tr><td scope="row"><font>Anti-arthritics</font></td>
<td><font>328 (8)</font></td>
<td><font>321 (9)</font></td>
<td><font>304 (7)</font></td>
<td><font>316 (7)</font></td>
<td><font>417 (7)</font></td>
</tr><tr><td scope="row"><font>Blood  			 Modifiers</font></td>
<td><font>300 (9)</font></td>
<td><font>341 (10)</font></td>
<td><font>98 (10)</font></td>
<td><font>368 (8)</font></td>
<td><font>237 (16)</font></td>
</tr><tr><td scope="row"><font>Hormones</font></td>
<td><font>272 (10)</font></td>
<td><font>283 (11)</font></td>
<td><font>171 (8)</font></td>
<td><font>309 (9)</font></td>
<td><font>255 (11)</font></td>
</tr><tr><td colspan="6"><font> </font></td>
</tr><tr><td scope="row"><font>All  			 Therapeutic Categories ($ in millions)</font></td>
<td><font>5,427.4</font></td>
<td><font>3,572.4</font></td>
<td><font>297.7</font></td>
<td><font>1,003.0</font></td>
<td><font>554.2</font></td>
</tr><tr><td scope="row"><font>Total Top 10  			 Spending ($ in millions)</font></td>
<td><font>4,162.5</font></td>
<td><font>2,741.9</font></td>
<td><font>240.7</font></td>
<td><font>780.2</font></td>
<td><font>425.2</font></td>
</tr><tr><td scope="row"><font>Top 10  			 Categories as Percent of Total</font></td>
<td><font>76.7%</font></td>
<td><font>76.8%</font></td>
<td><font>80.8%</font></td>
<td><font>77.8%</font></td>
<td><font>76.7%</font></td>
</tr><tr><td colspan="6"><font><b>SOURCE</b>: MCBS, 2001.</font></td>
</tr></table><h2><a name="trend" id="trend">III. TRENDS IN ACTUAL AND PROJECTED PRESCRIPTION DRUG  		SPENDING, 1998-2005</a></h2>
<p>This section examines the socio-demographic changes occurring in the  		LTCF population from 1998-2001. Based upon estimates provided for prescription  		drug expenditures from 1998-2001, projected drug expending is estimated for  		2002-2005, the last year before implementation of the MMA.</p>
<p><b><i>Trends in characteristics of Medicare beneficiaries residing in  		LTCFs, 1998-2001</i></b>. The United States population residing in LTCFs  		remained relatively stable from 1998-2001, with the LTCF population growing  		1.6% over the three year period (<a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#figure2">Figure 2</a>). Growth,  		where it did occur, was primarily in ALF and OF residences: the number of  		individuals residing in ALF homes increased 33.2% in three years, and those  		residing in OF residences increased 10.8% over the same time period. Between  		1998 and 2001, the population residing in traditional NH declined by 3.4%.</p>
<table><tr><td><font><b><a name="figure2" id="figure2">FIGURE 2</a>. Trends in  			 LTCF Population, 1998-2001</b></font></td>
</tr><tr><td><img src="https://aspe.hhs.gov/system/files/images-reports-basic/68951/pdnatest-fig2.JPG" alt="line chart: trend in LTCF population, 1998-2001" /></td>
</tr><tr><td><font><b>SOURCE</b>: MCBS,  			 1998-2001.</font></td>
</tr></table><p>For the most part, characteristics of individuals residing in LTCFs  		remained stable over the four year study period. Of primary consequence to this  		analysis was the shift in coverage source income over time. Specifically, we  		observed a dramatic increase in the proportion of beneficiaries in long-term  		care who qualify for Medicare on the basis of SSDI (<a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#figure3">Figure  		3</a>). Indeed, in the total LTCF Medicare population, the proportion of the  		SSDI individuals has increased nearly four percentage points from 1998 to 2001.  		This growth is primarily driven by the burgeoning SSDI population residing in  		Other Facility settings.</p>
<table><tr><td><font><b><a name="figure3" id="figure3">FIGURE 3</a>. Trends in  			 Proportion of LTCF Medicare Beneficiaries Eligible by SSDI Eligibility,  			 1998-2001</b></font></td>
</tr><tr><td><img src="https://aspe.hhs.gov/system/files/images-reports-basic/68951/pdnatest-fig3.JPG" alt="line chart: trends in proportion of LTCF Medicare beneficiaries eligible by SSDI eligibility, 1998-2001" /></td>
</tr><tr><td><font><b>SOURCE</b>: MCBS,  			 1998-2001.</font></td>
</tr></table><p><b><i>Trends in prescription drug utilization and spending,  		1998-2001</i></b>. Total prescription spending increased steadily between 1998  		and 2001 (<a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#figure4">Figure 4</a>). Mean annual growth in prescription  		drug spending across all LTCFs was 11.9% over the three year period, with the  		greatest growth noted in ALFs.</p>
<table><tr><td><font><b><a name="figure4" id="figure4">FIGURE 4</a>. Mean  			 Annual Growth in Prescription Drug Expenditures in LTCFs, by Facility Type  			 (1998-2001)</b></font></td>
</tr><tr><td><img src="https://aspe.hhs.gov/system/files/images-reports-basic/68951/pdnatest-fig4.JPG" alt="bar chart: mean annual growth in prescription drug expenditures in LTCFs, by facility type" /></td>
</tr><tr><td><font><b>SOURCE</b>: MCBS,  			 1998-2001.</font></td>
</tr></table><p><b><i>Actual and projected prescription drug expenditures,  		1998-2005</i></b>. Based on actual national estimates from 1998-2001, total  		prescription drug expenditures for all LTCFs are projected through 2005. Two  		types of projections are presented that illustrate the consequences of  		different modeling assumptions. The first type of projection uses a linear  		projection which assumes that total prescription drug expenditures increase at  		a constant rate. This is shown by the resultant straight line shown in the  		projected numbers.</p>
<p>The non-linear projections fit the actual spending estimates for  		1998-2001 to an exponential growth series using two methods. The first  		non-linear growth trend is based solely upon total prescription drug  		expenditures and projects them forward as a unit regardless of the individual  		growth patterns of the therapeutic classifications contained with it. </p>
<p>The second type of non-linear trend accounts for differing individual  		growth rates in therapeutic categories rates and so projects them forward  		separately and then sums them collectively to come up with a new total  		expenditure. Because individual, categorical growth rates are accounted for,  		this results in larger total expenditures.</p>
<table><tr><td><font><b><a name="figure5" id="figure5">FIGURE 5</a>.  			 Prescription Drug Expenditures by Therapeutic Class, 1998-2001</b></font></td>
</tr><tr><td><img src="https://aspe.hhs.gov/system/files/images-reports-basic/68951/pdnatest-fig5.JPG" alt="line chart: prescription drug expenditures by therapeutic class, 1998-2001" /></td>
</tr><tr><td><font><b>SOURCE</b>: MCBS,  			 1998-2001.</font></td>
</tr></table><p>We found that two therapeutic categories are primarily responsible for  		prescription drug spending growth between 1998 and 2001: the psychotherapeutic  		agents and gastrointestinal agents (<a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#figure5">Figure 5</a>). In regard  		to the psychotherapeutic agents, this spending growth is due to both increases  		in utilization as well as increases in spending. The heaviest users of  		psychotherapeutic agents are SSDI Medicare beneficiaries, the majority of whom  		also are dually eligible for Medicaid.</p>
<p>Based on the three different approaches, total prescription drug  		expenditures in LTCFs are estimated to range from $7.8-$10.5 billion (<a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#figure6">Figure 6</a> and <a href="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html#table8">Table 8</a>). The different  		types of projections of prescription drug spending for 2005 illustrate the  		large differences the modeling assumptions can create. For example, projected  		2005 expenditures using a linear projection model shows expenditures at $7.8  		billion while the non-linear total expenditure projection estimate is $9.4  		billion, and the non-linear projections based on the sum of individually  		trended therapeutic classification rises still further to $10.5 billion. The  		following table shows the projected estimates and percentage increases from  		2001, the last year of data.</p>
<table><tr><td colspan="9"><font><b><a name="table8" id="table8">TABLE 8</a>. Actual and Projected  			 Prescription Drug Expenditures, 1998-2005</b></font></td>
</tr><tr><td rowspan="2" scope="col"><font><b> </b></font></td>
<td colspan="4" scope="col"><font><b>Projected Expenditures  			 by  Different Projection Models  ($ in  			 millions)</b></font></td>
<td colspan="4" scope="col"><font><b>% Increase  from  			 2001 Estimates  </b></font></td>
</tr><tr><td scope="col"><font><b>2002</b></font></td>
<td scope="col"><font><b>2003</b></font></td>
<td scope="col"><font><b>2004</b></font></td>
<td scope="col"><font><b>2005</b></font></td>
<td scope="col"><font><b>2002</b></font></td>
<td scope="col"><font><b>2003</b></font></td>
<td scope="col"><font><b>2004</b></font></td>
<td scope="col"><font><b>2005</b></font></td>
</tr><tr><td scope="row"><font>Linear</font></td>
<td><font>5,918</font></td>
<td><font>6,547</font></td>
<td><font>7,175</font></td>
<td><font>7,803</font></td>
<td><font>9.0%</font></td>
<td><font>20.6%</font></td>
<td><font>32.2%</font></td>
<td><font>43.8%</font></td>
</tr><tr><td scope="row"><font>Non-linear,  			 total $</font></td>
<td><font>6,141</font></td>
<td><font>7,087</font></td>
<td><font>8,180</font></td>
<td><font>9,441</font></td>
<td><font>13.1%</font></td>
<td><font>30.6%</font></td>
<td><font>50.7%</font></td>
<td><font>73.9%</font></td>
</tr><tr><td scope="row"><font>Non-linear,  			 Sum of Therapeutic Categories  </font></td>
<td><font>  6,252  </font></td>
<td><font>  7,381  </font></td>
<td><font>  8,780  </font></td>
<td><font>  10,524  </font></td>
<td><font>  15.2%  </font></td>
<td><font>  36.0%  </font></td>
<td><font>  61.8%  </font></td>
<td><font>  93.9%  </font></td>
</tr><tr><td colspan="9"><font><b>SOURCE</b>: MCBS, 1998-2001.</font></td>
</tr></table><table><tr><td><font><b><a name="figure6" id="figure6">FIGURE 6</a>. Actual and  			 Projected Prescription Drug Spending, 1998-2005</b></font></td>
</tr><tr><td><img src="https://aspe.hhs.gov/system/files/images-reports-basic/68951/pdnatest-fig6.JPG" alt="line chart: actual and projected prescription drug spending 1998-2005" /></td>
</tr><tr><td><font><b>SOURCE</b>: MCBS,  			 1998-2001.</font></td>
</tr></table><h3>Discussion</h3>
<p>In 2001, nearly 2.7 million Medicare beneficiaries living in NHs and  		other LTCFs spent more than $5.42 billion on prescription drugs. In the absence  		of any diagnostic or functional assessment, prescription drug spending as  		reported through the MCBS is largely driven by coverage source, with Medicaid  		being the largest payor of prescription drugs. The SSDI-eligible LTCF  		population, designated here as those Medicare beneficiaries aged less than 65,  		are growing as a proportion of Medicare beneficiaries and also constitute a  		driving force behind the number and types of prescription medication  		expenditures. Indeed, in 2001 Medicare beneficiaries designated as  		SSDI-eligible spent, on average, $828 more on prescription drugs than their  		counterparts qualifying for Medicare on the basis of age.</p>
<p>Overall population growth in LTCFs from 1998-2001 has been nominal,  		spurred by growth in two sectors -- ALF and OF. This increase in the OF  		population is primarily due to increases in the disabled population, which is  		inherently the more expensive population in terms of prescription drug  		spending. In contrast, growth in ALFs, while notable, is driven primarily by  		relatively healthy Medicare-eligibles age 65 and older and still represents a  		relatively small proportion of total LTCF beds. The differential findings for  		coverage type and eligibility status suggest that these populations are very  		different in terms of prescription drug utilization and expenditures patterns  		and should be considered as such in future policy and research analyses.</p>
<p>In general, the Top 10 therapeutic categories accounted for  		approximately three-quarters of all prescription drug spending in LTCFs,  		regardless of facility type, coverage source, and eligibility status. Thus, any  		efforts to manage the use and spending of prescription drugs in LTCFs most  		likely would focus on these classes. Of course, as this brief illustrates,  		there is variability in which categories are most frequently used; these  		differences are most notable when examined by facility type, coverage source,  		and eligibility status because these groups embody different medical conditions  		and needs. What is not examined here and may be addressed in future analysis is  		how clinical variability, in terms of actual diagnoses as well as  		severity-of-illness, influences drug spending. Under the MMA, Medication  		Management Therapy services are provided to individuals with a high disease  		and/or drug burden, which may ultimately alter drug spending patterns in the  		future.</p>
<p>Psychotherapeutic agents were the most commonly utilized therapeutic  		class, as well as the most expensive class, accounting for more than  		one-quarter of all drug spending. Psychotherapeutic drug use was driven by  		disabled individuals who were dually eligible for Medicare and Medicaid. Given  		that estimates provided here are from 2001, it demonstrates that  		psychotherapeutics are likely to constitute a large proportion of LTCF drug  		spending under the MMA. Indeed, under the Part D provisions, many of the  		psychotherapeutic pharmacologic classes, including the antidepressants, the  		antipsychotics, and the anticonvulsants (many of which are used to treat mental  		health conditions) enjoy special protections including the provision that all  		drugs in that class be excluded from Prescription Drug Plan formularies. These  		protected classes, however, are still subject to prior authorization and  		differential copayments, which may influence utilization patterns. Thus, the  		psychotherapeutic agents remain a broad therapeutic category that may warrant  		monitoring as the MMA unfolds. The gastrointestinal agents are the second most  		expensive therapeutic class, and account for another one in ten prescription  		drug dollars. The next three most expensive therapeutic classes warrant  		scrutiny in the future: the autonomic agents, comprised of some  		antihypertensive agents (e.g., beta-blockers) and drugs used to treat  		Parkinsons disease, cardiovascular drugs, and the central nervous system  		drugs, which include the anticonvulsant agents such as lamotrigine and  		gabapentin. </p>
<p><b><i>Limitations</i></b>. Findings should be considered in the context  		of several limitations. We estimate prescription spending growth to continue at  		approximately 11% annually. It is important to note, however, that projection  		models are inherently sensitive to assumptions, as evidenced by the wide  		variability of total growth estimates ranging from 44% to 94%, depending upon  		model and when referenced to 2001 spending. The projection of prescription  		spending into the future is always sensitive endeavor and subject to cumulative  		influences of the assumptions behind the growth model. The reader is cautioned  		to view these projections as rough approximations to the degree of growth, and  		not as absolute numbers. Our projected estimates of prescription drug  		expenditures growth are basic; detailed projections were beyond the scope of  		this study. Further work in projecting expenditures forward should consider the  		use of constant dollars, using the GDP or other inflation adjuster, as well as  		decomposition of spending to reflect true price differences from growth due to  		increased utilization and/or therapeutic drug mix. </p>
<p>For one, the findings only are generalizable to Medicare beneficiaries,  		as the MCBS does not contain information on LTCF residents who are not  		Medicare-eligible. We also exclude facilities that do not have continuous  		(24/7) nursing care and centralized medication management; thus, our findings  		of prescription use and spending in ALF and OFs are likely to be  		underestimated. In addition, the pricing algorithm used for this analysis has  		only been used to price prescription drug events among MCBS respondents  		residing in the community and there is no published benchmark to which we can  		compare for validity of our LTCF prescription drug expenditures. This will be  		addressed in a future sensitivity analysis using proprietary data from a large  		prescription drug service provider, as well as in another Policy Brief  		comparing prescription drug expenditures among LTCF-residing beneficiaries to  		their community-dwelling counterparts. Finally, the findings from this report  		generalize to the Medicare population residing in LTCFs and do not capture  		beneficiaries residing in the community. Future work will compare prescription  		drug spending in these two beneficiary populations.</p>
<h3>Conclusions</h3>
<p>This brief presents the first national estimates of prescription drug  		expenditures in LTCFs in the United States. These findings provide a useful  		benchmark for policy-makers and payors of prescription drugs for the LTCF  		Medicare population. Further research and analysis are required in several  		areas, including: estimating monthly prescription drug utilization and  		expenditures to the facility in which they were incurred; the use of  		multivariable methods which control for various covariates, including disease  		burden and severity-of-illness; the continuous updating of MCBS files to  		provide current data; the continued application of the pricing algorithm to the  		IDA data and generation of more recent expenditures estimates; decomposition of  		spending by use, price, and therapeutic mix; and the application of more  		sophisticated modeling techniques to better approximate projected prescription  		drug spending. </p>
<h2><a name="rptlist" id="rptlist">LIST OF REPORTS</a></h2>
<p><b><i>Prescription Drug Spending by Medicare Beneficiaries in  		Institutional and Residential Settings, 1998-2001</i></b></p>
<blockquote><p>HTML version:  		  <a href="http://aspe.hhs.gov/daltcp/reports/2007/pdspend.htm">http://aspe.hhs.gov/daltcp/reports/2007/pdspend.htm</a>  		  </p>
<p>PDF version:  		  <a href="http://aspe.hhs.gov/daltcp/reports/2007/pdspend.pdf">http://aspe.hhs.gov/daltcp/reports/2007/pdspend.pdf</a>  		  </p>
</blockquote>
<p><b><i>POLICY BRIEF #1: National Estimates of Prescription Drug  		Utilization and Expenditures in Long-Term Care Facilities</i></b> </p>
<blockquote><p>HTML version:  		  <a href="http://aspe.hhs.gov/daltcp/reports/2006/pdnatest.htm">http://aspe.hhs.gov/daltcp/reports/2006/pdnatest.htm</a>  		  </p>
<p>PDF version:  		  <a href="https://s3-sa-east-1.amazonaws.com/ea-web-scrapes/aspe.hhs.gov/system/files/pdf/75056/pdnatest.pdf">http://aspe.hhs.gov/daltcp/reports/2006/pdnatest.pdf</a>  		  </p>
</blockquote>
<p><b><i>POLICY BRIEF #2: A National Comparison of Prescription Drug  		Expenditures by Medicare Beneficiaries Living in the Community and Long-Term  		Care Facility Settings</i></b> </p>
<blockquote><p>HTML version:  		  <a href="http://aspe.hhs.gov/daltcp/reports/2007/pdnatcom.htm">http://aspe.hhs.gov/daltcp/reports/2007/pdnatcom.htm</a>  		  </p>
<p>PDF version:  		  <a href="http://aspe.hhs.gov/daltcp/reports/2007/pdnatcom.pdf">http://aspe.hhs.gov/daltcp/reports/2007/pdnatcom.pdf</a>  		  </p>
</blockquote>
<p><i><b>POLICY BRIEF #3: Drug Use and Spending for Medicare Beneficiaries  		During Part A Qualifying Skilled Nursing Facility Stays and Non-Qualifying  		Long-Term Care Facility Stays</b></i></p>
<blockquote><p>HTML version:  		  <a href="http://aspe.hhs.gov/daltcp/reports/2007/druguse.htm">http://aspe.hhs.gov/daltcp/reports/2007/druguse.htm</a>  		  </p>
<p>PDF version:  		  <a href="http://aspe.hhs.gov/daltcp/reports/2007/druguse.pdf">http://aspe.hhs.gov/daltcp/reports/2007/druguse.pdf</a>  		  </p>
</blockquote>
<h2><a name="notes" id="notes">NOTES</a></h2>
<ol><li>
<p><a name="note1" id="note1">Stuart</a> B, Simoni-Wastila L, Shaffer T, Baysac F,  			 Shea D. Coverage and Use of Prescription Drugs in Nursing Homes: Implications  			 for the Medicare Modernization Act. <i>Medical Care</i>. March 2006,  			 44(3):243-249. Briesacher BA, Limcangco R, Simoni-Wastila L, Doshi JA, Levens  			 SR, Shea DG, and Stuart B. The quality of antipsychotic prescribing in nursing  			 homes. <i>Archives of Internal Medicine</i>. June 2005; 165:1280-1285.  			 Briesacher B, Limcangco R, Simoni-Wastila L, Doshi J, Gurwitz J. Evaluation of  			 nationally-mandated drug use reviews to improve patient safety in nursing  			 homes: a natural experiment. <i>Journal of the American Geriatric Society</i>.  			 June 2005; 53(6); 991-998. Simoni-Wastila L, Stuart B, and Shaffer T.  			 Over-the-Counter drug use by Medicare beneficiaries in nursing homes:  			 implications for practice and policy. <i>Journal of the American Geriatrics  			 Society</i>. Accepted for publication and available online August 3, 2006  			 (<a href="http://www.blackwell-synergy.com/doi/abs/10.1111/j.1532-5415.2006.00870">http://www.blackwell-synergy.com/doi/abs/10.1111/j.1532-5415.2006.00870</a>).</p>
</li>
<li>
<p><a name="note2" id="note2">This</a> effort was undertaken in consultation with  			 CMS.</p>
</li>
<li>
<p><a name="note3" id="note3">Simoni-Wastila</a> L, Stuart B, Shaffer T.  			 Over-the-Counter drug use by Medicare beneficiaries in nursing homes:  			 implications for practice and policy. <i>Journal of the American Geriatrics  			 Society</i>. Accepted for publication and available online August 3, 2006  			 (<a href="http://www.blackwell-synergy.com/doi/abs/10.1111/j.1532-5415.2006.00870">http://www.blackwell-synergy.com/doi/abs/10.1111/j.1532-5415.2006.00870</a>).</p>
</li>
</ol>
  <div class="download_report">

                        <div class="pdf-prev">
                <img src="https://aspe.hhs.gov/system/files/pdfpreview/093df790a06c6ab04fe647469920acc6.png" alt="Preview" title="Preview" />            </div>
                <a class="btn btn-sm btn-default download-file"
           href="https://s3-sa-east-1.amazonaws.com/ea-web-scrapes/aspe.hhs.gov/system/files/pdf/75056/pdnatest.pdf">Download</a>

        <p class="download_title">&quot;pdnatest.pdf&quot;
            (pdf,
            783.15Kb)</p>
        <p>Note: Documents in PDF format require the <a href="http://www.adobe.com/products/acrobat/readstep2.html">Adobe
                Acrobat Reader&reg;</a>. If you experience problems with PDF documents, please <a
                href="http://www.adobe.com/products/acrobat/readstep2.html">download the latest version of the
                Reader&reg;</a>
        </p>
    </div>
<div class="group-tags"><div class="field-label">Tags:&nbsp;</div><a href="https://aspe.hhs.gov/terms/prescriptions-and-pharmacy-services">Prescriptions and Pharmacy Services</a><a href="https://aspe.hhs.gov/terms/prescription-drugs">Prescription Drugs</a><a href="../terms/publications-2.html">Publications</a><a href="../terms/disability-aging-and-long-term-care-research.html">Disability, Aging and Long-Term Care Research</a><a href="https://aspe.hhs.gov/terms/drugs-medical-devices-and-pharmacy-services">Drugs, Medical Devices, and Pharmacy Services</a><a href="../taxonomy/term/16281.1.html">Medicare</a></div>  </div>

      <footer>
          </footer>

    <div id="block-webform-client-block-158521" class="widget block block-webform" >


  <div id="webform-ajax-wrapper-158521"><form class="webform-client-form webform-client-form-158521" action="national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities.html" method="post" id="webform-client-form-158521" accept-charset="UTF-8"><div><div class="webform-progressbar">



  </div>
<div  class="form-item webform-component webform-component-radios webform-component--was-this-page-helpful">
  <label for="edit-submitted-was-this-page-helpful">Was this page helpful? <span class="form-required" title="This field is required.">*</span></label>
 <div id="edit-submitted-was-this-page-helpful" class="form-radios"><div class="form-type-radio form-item-submitted-was-this-page-helpful form-item radio">
 <input required="required" type="radio" id="edit-submitted-was-this-page-helpful-1" name="submitted[was_this_page_helpful]" value="1" class="form-radio" />  <label for="edit-submitted-was-this-page-helpful-1">Yes </label>

</div>
<div class="form-type-radio form-item-submitted-was-this-page-helpful form-item radio">
 <input required="required" type="radio" id="edit-submitted-was-this-page-helpful-2" name="submitted[was_this_page_helpful]" value="0" class="form-radio" />  <label for="edit-submitted-was-this-page-helpful-2">No </label>

</div>
</div>
</div>
<input type="hidden" name="details[sid]" />
<input type="hidden" name="details[page_num]" value="1" />
<input type="hidden" name="details[page_count]" value="4" />
<input type="hidden" name="details[finished]" value="0" />
<input type="hidden" name="form_build_id" value="form-UU7h_7UFWzHfs1Q4mxUf3J76icxgFZC72SbnhBzjonE" />
<input type="hidden" name="form_id" value="webform_client_form_158521" />
<input type="hidden" name="webform_ajax_wrapper_id" value="webform-ajax-wrapper-158521" />
<div class="form-actions"><input class="webform-next button-primary btn btn-default form-submit" type="submit" id="edit-webform-ajax-next-158521" name="op" value="Next &gt;" /></div>
<div class="is-useful-disclaimer"> <a href="https://aspe.hhs.gov/%23" class="" title="Survey Disclaimer" data-toggle="modal" data-target="#disclamerModal">Form Approved OMB# 0990-0379 Exp. Date 8/31/2017</a></div>
<div class="modal fade" id="disclamerModal" tabindex="-1" role="dialog" aria-labelledby="disclamerModalLabel">
  <div class="modal-dialog" role="document">
    <div class="modal-content">
      <div class="modal-header">
        <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">&times;</span></button>
        <h2 class="modal-title" id="disclamerModalLabel">Survey Disclaimer</h2>
      </div>
      <div class="modal-body">
         According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0990-0379. The time required to complete this information collection is estimated to average 5 minutes per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: U.S. Department of Health & Human Services, OS/OCIO/PRA, 200 Independence Ave., S.W., Suite 336-E, Washington D.C. 20201, Attention: PRA Reports Clearance Officer.      </div>
    </div>
  </div>
</div></div></form></div>
  </div> <!-- /.block -->
<meta  itemscope="" itemid="https://aspe.hhs.gov/pdf-report/national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities" itemref="md1" /><meta  itemscope="" itemid="https://aspe.hhs.gov/basic-report/national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities" itemref="md2 md3 md5 md7 md9 md11 md13 md15" /><meta  itemscope="" itemid="https://aspe.hhs.gov/terms/prescriptions-and-pharmacy-services" id="md5" itemref="md4" /><meta  itemscope="" itemid="https://aspe.hhs.gov/terms/prescription-drugs" id="md7" itemref="md6" /><meta  itemscope="" itemid="https://aspe.hhs.gov/terms/publications-2" id="md9" itemref="md8" /><meta  itemscope="" itemid="https://aspe.hhs.gov/terms/disability-aging-and-long-term-care-research" id="md11" itemref="md10" /><meta  itemscope="" itemid="https://aspe.hhs.gov/terms/drugs-medical-devices-and-pharmacy-services" id="md13" itemref="md12" /><meta  itemscope="" itemid="https://aspe.hhs.gov/terms/medicare-0" id="md15" itemref="md14" />
                          </div>










      </div>

          </div>


      </div>



      <footer  class="nd-region">



          <div class = "container">

      <div  class="row" id="Footer">










                                    <div  id="footer_sitemap-footer_sitemap" class="col-sm-6 col-md-6 col-lg-4 ">

                              <div id="block-footer-sitemap-footer-sitemap" class="widget block block-footer-sitemap" >


  <div id="footer-sitemap" class="clearfix">
  <div class="fs-block-content"><div class="menu-footer-utility"><ul class="footer_links_menu-footer-utility total-items-2 parent-items-0 single-items-0"><li class="menu-5021 depth-1 total-children-8 parent-children-0 single-children-8  first"><a href="../images/exit_disclaimer.jpg.html" title="look at ASPE Home" class="fs-root-link">ASPE Home</a><ul class="footer_links_menu-footer-utility total-items-8 parent-items-0 single-items-0"><li class="menu-5026 depth-1 fs-no-children  first"><a href="http://www.hhs.gov/" title="look at HHS Home">HHS Home</a></li>
<li class="menu-66281 depth-1 fs-no-children"><a href="http://www.usa.gov/" title="look at USA.gov">USA.gov</a></li>
<li class="menu-66316 depth-1 fs-no-children"><a href="https://oig.hhs.gov/" title="look at Office of the Inspector General">Office of the Inspector General</a></li>
<li class="menu-66321 depth-1 fs-no-children"><a href="http://www.whitehouse.gov" title="look at The White House">The White House</a></li>
<li class="menu-5046 depth-1 fs-no-children"><a href="http://www.hhs.gov/Accessibility.html" title="look at Accessibility">Accessibility</a></li>
<li class="menu-66326 depth-1 fs-no-children"><a href="http://www.hhs.gov/about/budget/index.html" title="look at Budget/Performance">Budget/Performance</a></li>
<li class="menu-2551 depth-1 fs-no-children"><a href="http://www.hhs.gov/Privacy.html" title="look at Privacy Policy">Privacy Policy</a></li>
<li class="menu-197776 depth-1 fs-no-children  last"><a href="https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html" title="Nondiscrimination Notice">Nondiscrimination Notice</a></li>
</ul></li>
<li class="menu-5051 depth-1 total-children-4 parent-children-0 single-children-4  last"><a href="http://www.hhs.gov/foia/" title="look at FOIA" class="fs-root-link">FOIA</a><ul class="footer_links_menu-footer-utility total-items-4 parent-items-0 single-items-0"><li class="menu-5056 depth-1 fs-no-children  first"><a href="http://www.hhs.gov/open/recordsandreports/plainwritingact/index.html" title="look at Plain Writing Act">Plain Writing Act</a></li>
<li class="menu-5061 depth-1 fs-no-children"><a href="http://www.hhs.gov/asa/eeo/no_fear_bullet_3.html" title="look at No Fear Act">No Fear Act</a></li>
<li class="menu-5066 depth-1 fs-no-children"><a href="http://www.hhs.gov/Disclaimer.html" title="look at Disclaimers">Disclaimers</a></li>
<li class="menu-2546 depth-1 fs-no-children  last"><a href="http://www.hhs.gov/plugins.html" title="look at Viewers &amp; Players">Viewers &amp; Players</a></li>
</ul></li>
</ul></div>
</div>
</div>

  </div> <!-- /.block -->

                          </div>


                                    <div  class="col-sm-6 col-md-6 col-lg-5 " id="stability_cms-contact_us">

                              <div id="block-stability-cms-contact-us" class="widget block block-stability-cms" >


  <div class="contacts-widget widget widget__footer">
	<div class="widget-content">
		<ul class="contacts-info-list">
      			<li>
<!--				<i class="fa fa-map-marker">Address</i>-->
                <div class="info-icons">
                    <img  alt="map" class= 'map-icons' src="../sites/all/themes/stability/stability_aspe/images/map.png"/>
                </div>
                <div class="info-item">
					Assistant Secretary for Planning and Evaluation, Room 415F<br />
U.S. Department of Health and Human Services<br />
200 Independence Avenue, SW<br />
Washington, D.C. 20201				</div>
			</li>
            			<li>
<!--				<i class="fa fa-phone">phone</i>-->
                <div class="info-icons">
                    <img alt="phone" src="../sites/all/themes/stability/stability_aspe/images/phone.png"/>
                </div>
				<div class="info-item">
					+1 202.690.7858				</div>
			</li>
            			<li>
<!--				<i class="fa fa-envelope">email</i>-->
                <div class="info-icons">
                    <img alt="mail" src="../sites/all/themes/stability/stability_aspe/images/mail-white.png"/>
                </div>
				<span class="info-item">
					<a href="mailto:osaspeinfo@hhs.gov">osaspeinfo@hhs.gov</a>
				</span>
			</li>
      			                					</ul>
	</div>
</div>
  </div> <!-- /.block -->

                          </div>


                                    <div  class="col-sm-6 col-md-6 col-lg-3 " id="footer">

                              <div id="block-block-36" class="widget block block-block" >

        <div class="title-accent">
			<h3 class = "widget-title" ><span>Sign-up</span> for Email Updates</h3>
		</div>

  <div class="email_updates">
<button class="btn btn-default" name="subscribe-button" type="submit" value="subscribe">subscribe</button>
</div>
  </div> <!-- /.block -->

                          </div>


                                    <div  class="col-sm-6 col-md-6 col-lg-12 " id="menu-menu-footer-language-menu">

                              <div id="block-menu-menu-footer-language-menu" class="widget block block-menu" >

        <div class="title-accent">
			<h3 class = "widget-title" ><span>Language</span> Assistance Available</h3>
		</div>

  <ul class="menu"><li class="first expanded"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#spanish" title="Español">Español</a><ul><li class="first leaf"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#chinese" title="繁體中文">繁體中文</a></li>
<li class="leaf"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#vietnamese" title="Tiếng Việt">Tiếng Việt</a></li>
<li class="last leaf"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#korean" title="한국어">한국어</a></li>
</ul></li>
<li class="expanded"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#tagalog" title="Tagalog">Tagalog</a><ul><li class="first leaf"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#russian" title="Русский">Русский</a></li>
<li class="leaf"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#arabic" title="العربية">العربية</a></li>
<li class="last leaf"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#creole" title="Kreyòl Ayisyen">Kreyòl Ayisyen</a></li>
</ul></li>
<li class="expanded"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#french" title="Français">Français</a><ul><li class="first leaf"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#polish" title="Polski">Polski</a></li>
<li class="leaf"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#portuguese" title="Português">Português</a></li>
<li class="last leaf"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#italian" title="Italiano">Italiano</a></li>
</ul></li>
<li class="last expanded"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#german" title="Deutsch">Deutsch</a><ul><li class="first leaf"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#japanese" title="日本語">日本語</a></li>
<li class="leaf"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#farsi" title="فارسی">فارسی</a></li>
<li class="last leaf"><a href="https://www.hhs.gov/civil-rights/for-individuals/language-assistance/index.html#english" title="English">English</a></li>
</ul></li>
</ul>
  </div> <!-- /.block -->

                          </div>


      </div>

          </div>


      </footer>


    <!--/PAGEWATCH-->
    <div class="footer-copyright">
      <div class="container">
        <div class="row">
          <div class="col-sm-6 col-md-4">
                        </div>
          <div class="col-sm-6 col-md-8">
            <div class="social-links-wrapper">
              <span class="social-links-txt">Connect with us</span>
              <ul class="social-links social-links__dark">
                                                  <li><a href="http://twitter.com/hhs_aspe"><img alt="twitter" src="../sites/all/themes/stability/stability_aspe/images/tw-grey.png"/></a></li>
                                <!--                --><!--                  <li><a href="http://--><!--"><img alt="linkedin" src="--><!--/images/linkedin-grey.png"/></a></li>-->
<!--                -->
                                                              </ul>
            </div>
          </div>
        </div>
      </div>
    </div>

  </div>
</div>  <script type="text/javascript" src="../sites/default/files/advagg_js/js__VWRymaMz6HfrhnrcJNGcDiSvLVrvhaXvBa7nrBYy8gc__jntPwP3D6myJZH1jW19fXrk5cYMHGRL8NQION22VSEA__YASpjlMF4TMWgxnen_4K9EYMAww1U3QElt83Z7yKaXw.js"></script>
<script type="text/javascript" src="https://s7.addthis.com/js/300/addthis_widget.js#pubid=ra-5486d15a696bff0c"></script>
<script type="text/javascript" src="../sites/default/files/advagg_js/js__g6mKbcakHxQkz4ZHYaxdO_xqONINvRMgsHh1zAK-fr0__ATHtEmHaeZ0jidpGU22EkhmPDBSgjD8z0bVDQMI-BIY__YASpjlMF4TMWgxnen_4K9EYMAww1U3QElt83Z7yKaXw.js"></script>
<script type="text/javascript" src="../sites/default/files/advagg_js/js__KUp4PrfOt9BSXUVl8Ctb3dhCMBe4MNVMeb4Gyorx8yY__7g4BeXscCIZAfuu1vxsCj2RIemg-eEK0QpChP9LDmFQ__YASpjlMF4TMWgxnen_4K9EYMAww1U3QElt83Z7yKaXw.js"></script>
<script type="text/javascript" src="../sites/default/files/advagg_js/js__PNjAgubM_3xXRLp4uLsYnv8wQAdT89-RYkSPxT6T45c__rFQwFK4pA5ZaWZSF7FPTfKbbpus0h-5IS8ayrNZGrb4__YASpjlMF4TMWgxnen_4K9EYMAww1U3QElt83Z7yKaXw.js"></script>
<script type="text/javascript" src="../sites/default/files/advagg_js/js__vQiLul2UcfC4nBAR09mhYVBYzRmiNDm2dj3GgSubV38__w84oZe-ZODKe7XnnlbrjV4IWHISOy4PioFEMVgx9hZo__YASpjlMF4TMWgxnen_4K9EYMAww1U3QElt83Z7yKaXw.js"></script>
<script type="text/javascript" src="../sites/default/files/advagg_js/js__QJw3g0kOdwsv4twSZLP931zBzsHy50VEHpEN_znIitQ__A6QOuWXElDipBM2iChbWhjAAt3KlUwZ-jODoxdpbwiw__YASpjlMF4TMWgxnen_4K9EYMAww1U3QElt83Z7yKaXw.js"></script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
jQuery.extend(Drupal.settings,{"basePath":"\/","pathPrefix":"","ajaxPageState":{"theme":"stability_aspe","theme_token":"f1gwBaazoXCGpahW2oIEv8AfoLJLHICFvGFIUgb8LYM","jquery_version":"1.10","css":{"modules\/system\/system.base.css":1,"modules\/system\/system.messages.css":1,"sites\/all\/modules\/custom\/aspe_nodes\/theme\/css\/footable.css":1,"sites\/all\/modules\/custom\/aspe_nodes\/theme\/css\/aspe_nodes.admin.css":1,"sites\/all\/modules\/custom\/aspe_views\/theme\/css\/aspe_views.admin.css":1,"sites\/all\/modules\/forked\/book\/book.css":1,"profiles\/openpublic\/modules\/contrib\/date\/date_api\/date.css":1,"profiles\/openpublic\/modules\/contrib\/date\/date_popup\/themes\/datepicker.1.7.css":1,"modules\/field\/theme\/field.css":1,"sites\/all\/modules\/contrib\/footer_sitemap\/footer_sitemap.css":1,"modules\/node\/node.css":1,"modules\/user\/user.css":1,"sites\/all\/modules\/contrib\/extlink\/extlink.css":1,"profiles\/openpublic\/modules\/contrib\/views\/css\/views.css":1,"sites\/all\/modules\/contrib\/media\/modules\/media_wysiwyg\/css\/media_wysiwyg.base.css":1,"sites\/all\/libraries\/datatables\/dataTables.responsive.css":1,"profiles\/openpublic\/modules\/contrib\/ctools\/css\/ctools.css":1,"profiles\/openpublic\/modules\/contrib\/panels\/css\/panels.css":1,"profiles\/openpublic\/modules\/contrib\/webform\/css\/webform.css":1,"sites\/default\/files\/css\/follow.css":1,"sites\/all\/themes\/stability\/css\/bootstrap.min.css":1,"sites\/all\/themes\/stability\/css\/fonts\/font-awesome\/css\/font-awesome.min.css":1,"sites\/all\/themes\/stability\/vendor\/owl-carousel\/owl.carousel.css":1,"sites\/all\/themes\/stability\/vendor\/owl-carousel\/owl.theme.css":1,"sites\/all\/themes\/stability\/vendor\/magnific-popup\/magnific-popup.css":1,"sites\/all\/themes\/stability\/vendor\/mediaelement\/mediaelementplayer.css":1,"sites\/all\/themes\/stability\/css\/theme.css":1,"sites\/all\/themes\/stability\/css\/theme-elements.css":1,"sites\/all\/themes\/stability\/css\/animate.min.css":1,"sites\/all\/themes\/stability\/css\/skins\/red.css":1,"sites\/all\/themes\/stability\/stability_aspe\/css\/slideshow.css":1,"sites\/all\/themes\/stability\/stability_aspe\/css\/font-main.css":1,"sites\/all\/themes\/stability\/stability_aspe\/css\/styleless.less":1,"sites\/all\/themes\/stability\/css\/skins\/blue.css":1},"js":{"sites\/all\/modules\/contrib\/jquery_update\/replace\/jquery\/1.10\/jquery.js":1,"misc\/jquery.once.js":1,"misc\/drupal.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/external\/jquery.cookie.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/misc\/jquery.form.js":1,"misc\/ajax.js":1,"sites\/all\/modules\/contrib\/jquery_update\/js\/jquery_update.js":1,"sites\/all\/modules\/custom\/aspe\/theme\/js\/aspe.login-confirm.js":1,"sites\/all\/modules\/custom\/aspe_report\/modules\/aspe_databooks\/js\/aspe_databooks.js":1,"sites\/all\/modules\/custom\/aspe_nodes\/theme\/js\/aspe_nodes.highcharts.js":1,"sites\/all\/modules\/custom\/aspe_nodes\/theme\/js\/aspe_nodes.js":1,"sites\/all\/modules\/contrib\/extlink\/extlink.js":1,"sites\/all\/libraries\/datatables\/dataTables.min.js":1,"sites\/all\/libraries\/datatables\/dataTables.responsive.min.js":1,"sites\/all\/libraries\/highcharts\/highcharts.js":1,"sites\/all\/libraries\/highcharts\/highcharts.exporting.js":1,"sites\/all\/libraries\/highcharts\/highcharts.map.js":1,"sites\/all\/libraries\/highcharts\/highcharts.us-all.js":1,"sites\/all\/modules\/custom\/aspe_nodes\/theme\/js\/aspe_nodes.footable.js":1,"http:\/\/s7.addthis.com\/js\/300\/addthis_widget.js#pubid=ra-5486d15a696bff0c":1,"misc\/progress.js":1,"profiles\/openpublic\/modules\/contrib\/webform\/js\/webform.js":1,"profiles\/openpublic\/modules\/contrib\/field_group\/field_group.js":1,"sites\/all\/themes\/stability\/vendor\/jquery-migrate-1.2.1.min.js":1,"sites\/all\/themes\/stability\/vendor\/bootstrap.js":1,"sites\/all\/themes\/stability\/vendor\/jquery.flexnav.min.js":1,"sites\/all\/themes\/stability\/vendor\/jquery.hoverIntent.minified.js":1,"sites\/all\/themes\/stability\/vendor\/jquery.flickrfeed.js":1,"sites\/all\/themes\/stability\/vendor\/isotope\/jquery.isotope.min.js":1,"sites\/all\/themes\/stability\/vendor\/isotope\/jquery.isotope.sloppy-masonry.min.js":1,"sites\/all\/themes\/stability\/vendor\/isotope\/jquery.imagesloaded.min.js":1,"sites\/all\/themes\/stability\/vendor\/magnific-popup\/jquery.magnific-popup.js":1,"sites\/all\/themes\/stability\/vendor\/owl-carousel\/owl.carousel.min.js":1,"sites\/all\/themes\/stability\/vendor\/jquery.fitvids.js":1,"sites\/all\/themes\/stability\/vendor\/jquery.appear.js":1,"sites\/all\/themes\/stability\/vendor\/jquery.stellar.min.js":1,"sites\/all\/themes\/stability\/vendor\/snap.svg-min.js":1,"sites\/all\/themes\/stability\/js\/custom.js":1,"sites\/all\/themes\/stability\/stability_aspe\/js\/aspe.js":1,"sites\/all\/themes\/stability\/stability_aspe\/js\/html5shiv.min.js":1,"sites\/all\/themes\/stability\/stability_aspe\/js\/main-menu.js":1,"sites\/all\/themes\/stability\/stability_aspe\/js\/keyboard-control.js":1,"sites\/all\/themes\/stability\/stability_aspe\/js\/tabBehavior.js":1,"sites\/all\/themes\/stability\/stability_aspe\/js\/tileStringTrimmer.js":1}},"webform":{"conditionals":{"webform-client-form-158521":{"ruleGroups":[],"sourceMap":[],"values":[]}}},"ajax":{"edit-webform-ajax-next-158521":{"callback":"webform_ajax_callback","wrapper":"webform-ajax-wrapper-158521","progress":{"message":"","type":"throbber"},"event":"click","url":"\/system\/ajax","submit":{"_triggering_element_name":"op","_triggering_element_value":"Next \u003E"}}},"urlIsAjaxTrusted":{"\/system\/ajax":true,"\/basic-report\/national-estimates-prescription-drug-utilization-and-expenditures-long-term-care-facilities":true},"extlink":{"extTarget":"_blank","extClass":0,"extLabel":"(link is external)","extImgClass":0,"extSubdomains":0,"extExclude":"([a-z0-9]\\.gov)","extInclude":"","extCssExclude":"","extCssExplicit":"","extAlert":"_blank","extAlertText":"This website contains links to other federal and state agencies and private organizations. The Department of Health and Human Services (HHS) cannot attest to the accuracy of information provided by these nonfederal website links. Linking to nonfederal sites does not constitute an endorsement by HHS or any of its employees of the sponsors or the information and products presented on the sites. You will be subject to the destination site\u0027s privacy policy when you leave the ASPE website.\r\n\r\nThank you for visiting aspe.hhs.gov!","mailtoClass":0,"mailtoLabel":"(link sends e-mail)"},"stability":{"flickr_id":"52617155@N08","logo_sticky":"28"},"field_group":{"div":"full","hidden":"full"}});
//--><!]]>
</script>
  <script type="text/javascript">
<!--//--><![CDATA[//><!--
var addthis_config={pubid:"ra-5486d15a696bff0c",ui_click:false}
//--><!]]>
</script>


  <script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"bam.nr-data.net","licenseKey":"e4837db659","applicationID":"10708002","transactionName":"MwNaZBRSXEtXB0BdWQpJeVMSWl1WGQpbUFM7FllXA2xEUVMT","queueTime":0,"applicationTime":1291,"atts":"H0RZElxIT0U=","errorBeacon":"bam.nr-data.net","agent":""}</script></body>
</html>
